[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3938
1. Xia XY, Peng RX, Kong R, Yang ZQ, Chen X: [Effects of Angelica sinensis polysaccharides on hepatic drug metabolism enzymes activities in mice]. Zhongguo Zhong Yao Za Zhi; 2003 Feb;28(2):149-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of Angelica sinensis polysaccharides on hepatic drug metabolism enzymes activities in mice].
  • OBJECTIVE: To study the effects of Angelica sinensis Polysaccharides (ASP) on the hepatic drug metabolism enzymes activities in normal mice and those prednisolone (PSL)-induced liver injury.
  • CONCLUSION: ASP can modulate the activities of drug metabolism enzymes.
  • [MeSH-major] Angelica sinensis / chemistry. Cytochrome P-450 Enzyme System / metabolism. Drug-Induced Liver Injury / enzymology. Microsomes, Liver / enzymology. Polysaccharides / pharmacology
  • [MeSH-minor] Aminopyrine N-Demethylase / metabolism. Aniline Hydroxylase / metabolism. Animals. Glutathione Transferase / metabolism. Male. Mice. Mitochondria, Liver / enzymology. NADPH-Ferrihemoprotein Reductase / metabolism. Plants, Medicinal / chemistry. Prednisolone

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15015291.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Polysaccharides; 9035-51-2 / Cytochrome P-450 Enzyme System; 9PHQ9Y1OLM / Prednisolone; EC 1.14.14.- / Aniline Hydroxylase; EC 1.5.3.- / Aminopyrine N-Demethylase; EC 1.6.2.4 / NADPH-Ferrihemoprotein Reductase; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


2. Liu JY, Chen CC, Wang WH, Hsu JD, Yang MY, Wang CJ: The protective effects of Hibiscus sabdariffa extract on CCl4-induced liver fibrosis in rats. Food Chem Toxicol; 2006 Mar;44(3):336-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dried flower Hibiscus sabdariffa L. (HSE) extracts, a local soft drink material and medicinal herb, were studied for their protective effects against liver fibrosis induced using carbon tetrachloride (CCl(4)) in rats.
  • It also restored the decrease in glutathione content and inhibited the formation of lipid peroxidative products during CCl(4) treatment.
  • [MeSH-major] Antioxidants / pharmacology. Hibiscus / chemistry. Liver / drug effects. Liver Cirrhosis, Experimental / prevention & control. Phytotherapy. Plant Extracts / pharmacology
  • [MeSH-minor] Administration, Oral. Alanine Transaminase / metabolism. Animals. Aspartate Aminotransferases / metabolism. Carbon Tetrachloride / toxicity. Cells, Cultured. Dose-Response Relationship, Drug. Glutathione / metabolism. Lipid Peroxidation / drug effects. Male. Protective Agents / administration & dosage. Protective Agents / pharmacology. Protective Agents / therapeutic use. Rats. Rats, Wistar. Severity of Illness Index. Silymarin / administration & dosage. Silymarin / pharmacology. Silymarin / therapeutic use

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. CARBON TETRACHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176854.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Plant Extracts; 0 / Protective Agents; 0 / Silymarin; CL2T97X0V0 / Carbon Tetrachloride; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; GAN16C9B8O / Glutathione
  •  go-up   go-down


3. Yasmin S, Afroz B, Hyat B, D'Souza D: Occupational health hazards in women beedi rollers in Bihar, India. Bull Environ Contam Toxicol; 2010 Jul;85(1):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the health problems of 197 female beedi rollers in Patna, Bihar, India to ascertain the effects of beedi rolling on health.
  • The study found that more than 70% of the beedi rollers suffered from eye, gastrointestinal and nervous problems while more than 50% of the respondents suffered from respiratory problems, mostly throat burning and cough.
  • More than 75% of the respondents faced osteological problems.
  • [MeSH-minor] Adult. Alanine Transaminase / metabolism. Aspartate Aminotransferases / metabolism. Case-Control Studies. Central Nervous System Diseases / chemically induced. Central Nervous System Diseases / epidemiology. Central Nervous System Diseases / etiology. Eye Diseases / chemically induced. Eye Diseases / epidemiology. Eye Diseases / etiology. Female. Gastrointestinal Diseases / chemically induced. Gastrointestinal Diseases / epidemiology. Gastrointestinal Diseases / etiology. Hemoglobins / metabolism. Humans. India / epidemiology. Leukocytes / cytology. Leukocytes / drug effects. Leukocytes / metabolism. Liver Diseases / epidemiology. Liver Diseases / etiology. Middle Aged. Occupational Health. Socioeconomic Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20512312.001).
  • [ISSN] 1432-0800
  • [Journal-full-title] Bulletin of environmental contamination and toxicology
  • [ISO-abbreviation] Bull Environ Contam Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hazardous Substances; 0 / Hemoglobins; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


Advertisement
4. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L: Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol; 2009 Feb 28;15(8):942-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with viral hepatitis, chronic alcohol intake, drug abuse or other significant immune or metabolic hepatic pathology were excluded.
  • Treatment had to be taken daily at the same hour with no concomitant medication or alcohol consumption allowed.
  • [MeSH-major] Angiotensin II Type 1 Receptor Blockers / therapeutic use. Angiotensin Receptor Antagonists. Benzimidazoles / therapeutic use. Benzoates / therapeutic use. Fatty Liver / complications. Hypertension / drug therapy. Tetrazoles / therapeutic use. Valine / analogs & derivatives
  • [MeSH-minor] Alanine Transaminase / blood. Aspartate Aminotransferases / blood. Blood Pressure / drug effects. Female. Humans. Liver Function Tests. Male. Middle Aged. Patient Selection. Valsartan

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. VALSARTAN .
  • Hazardous Substances Data Bank. TELMISARTAN .
  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hypertension. 2006 May;47(5):1003-9 [16567593.001]
  • [Cites] Adv Ther. 2008 Nov;25(11):1141-74 [18972077.001]
  • [Cites] Hepatology. 2003 Apr;37(4):917-23 [12668987.001]
  • [Cites] Endocr Rev. 2003 Jun;24(3):261-71 [12788798.001]
  • [Cites] Blood Press. 2003;12(2):70-88 [12797627.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:1-10 [12814934.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8258-63 [12829792.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G642-51 [12773299.001]
  • [Cites] Korean J Gastroenterol. 2003 Aug;42(2):134-41 [14532718.001]
  • [Cites] Lab Invest. 2004 Feb;84(2):153-9 [14688800.001]
  • [Cites] Gut. 2004 Jul;53(7):923-4 [15194635.001]
  • [Cites] Clin Ther. 2004 Aug;26(8):1228-36 [15476904.001]
  • [Cites] Mol Endocrinol. 2000 Jan;14(1):99-113 [10628750.001]
  • [Cites] Circ Res. 2000 Sep 1;87(5):E1-9 [10969042.001]
  • [Cites] Semin Liver Dis. 2001;21(1):27-41 [11296694.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2001 May;10(3):321-9 [11342793.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] Hepatology. 2001 Jul;34(1):89-100 [11431738.001]
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):46-53 [11905837.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):134-40 [12105842.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:d69-77 [12456323.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1222-5 [15382153.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Curr Opin Nephrol Hypertens. 1997 Jan;6(1):28-34 [9051351.001]
  • [Cites] Hepatology. 1999 Mar;29(3):664-9 [10051466.001]
  • [Cites] Gut. 1999 Oct;45 Suppl 4:IV1-IV11 [10485854.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):209-18 [15690074.001]
  • [Cites] Semin Liver Dis. 2005;25(2):143-54 [15918143.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Hepatology. 2005 Jul;42(1):5-13 [15962320.001]
  • [Cites] Hypertens Res. 2005 Mar;28(3):209-14 [16097363.001]
  • [Cites] J Hypertens. 2005 Dec;23(12):2313-8 [16269974.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):322-6 [16482638.001]
  • [Cites] Hellenic J Cardiol. 2006 Jan-Feb;47(1):21-8 [16532712.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1807-21 [16697743.001]
  • [Cites] Hypertension. 2006 Jul;48(1):51-7 [16717145.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 4;346(3):658-64 [16774739.001]
  • [Cites] Metabolism. 2006 Sep;55(9):1149-54 [16919531.001]
  • [Cites] Diabetologia. 2006 Dec;49(12):3094-9 [17004092.001]
  • [Cites] J Hepatol. 2007 Apr;46(4):674-81 [17188388.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Apr 15;25(8):883-9 [17402991.001]
  • [Cites] J Gastrointestin Liver Dis. 2007 Mar;16(1):39-46 [17410287.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 May;292(5):E1280-7 [17213477.001]
  • [Cites] Diabetes Res Clin Pract. 2007 Aug;77(2):210-4 [17240472.001]
  • [Cites] J Hepatol. 2007 Jun;46(6):1026-33 [17336417.001]
  • [Cites] Adv Ther. 2007 Jan-Feb;24(1):146-53 [17526471.001]
  • [Cites] Horm Metab Res. 2007 May;39(5):372-6 [17533580.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1375-81 [17518368.001]
  • [Cites] Wien Med Wochenschr. 2007;157(9-10):223-7 [17564769.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S93-5 [17567477.001]
  • [Cites] Vasc Health Risk Manag. 2007;3(1):125-37 [17583183.001]
  • [Cites] Clin Sci (Lond). 2007 Aug;113(3):109-18 [17600527.001]
  • [Cites] J Hepatol. 2007 Sep;47(3):387-95 [17532087.001]
  • [Cites] Intern Med. 2007;46(17):1331-6 [17827829.001]
  • [Cites] Dig Dis Sci. 2007 Dec;52(12):3455-64 [17410441.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Dec 28;364(4):801-7 [17963695.001]
  • [Cites] J Pathol. 2008 Jan;214(2):199-210 [18161745.001]
  • [Cites] Eur J Pharmacol. 2008 Jan 28;579(1-3):426-32 [18078928.001]
  • [Cites] Hypertension. 2008 Feb;51(2):259-66 [18158351.001]
  • [Cites] Chin Med J (Engl). 2008 Jan 20;121(2):161-5 [18272044.001]
  • [Cites] Minerva Gastroenterol Dietol. 2008 Mar;54(1):7-18 [18299664.001]
  • [Cites] Obesity (Silver Spring). 2008 Apr;16(4):770-6 [18239590.001]
  • [Cites] J Int Med Res. 2008 Mar-Apr;36(2):237-43 [18380932.001]
  • [Cites] Diabetes. 2008 May;57(5):1405-13 [18184928.001]
  • [Cites] Hypertens Res. 2008 May;31(5):921-9 [18712048.001]
  • (PMID = 19248193.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Angiotensin Receptor Antagonists; 0 / Benzimidazoles; 0 / Benzoates; 0 / Tetrazoles; 80M03YXJ7I / Valsartan; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; HG18B9YRS7 / Valine; U5SYW473RQ / telmisartan
  • [Other-IDs] NLM/ PMC2653406
  •  go-up   go-down


5. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y: Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs; 2004 Apr;22(2):169-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SM-11355, a lipophilic platinum derivative, is a novel intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC).
  • Intra-arterial chemotherapy with SM-11355, which was well tolerated, showed promising antitumor activity in patients with HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Drugs, Investigational / administration & dosage. Liver Neoplasms / drug therapy. Organoplatinum Compounds / administration & dosage
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / blood. Antineoplastic Agents / chemistry. Confidence Intervals. Female. Humans. Infusions, Intra-Arterial. Lipids / administration & dosage. Lipids / blood. Lipids / chemistry. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2000 Dec;91(12):1326-32 [11123433.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):238-42 [2825961.001]
  • [Cites] J Vasc Interv Radiol. 2001 Jul;12(7):847-54 [11435541.001]
  • [Cites] Gan To Kagaku Ryoho. 1993 Aug;20(11):1485-8 [7690535.001]
  • [Cites] Oncology. 2002;62(3):228-33 [12065870.001]
  • [Cites] Cancer. 1978 May;41(5):1720-7 [647622.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Sep;21(13):2212-4 [7944442.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31 Suppl:S55-9 [1281046.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):276-83 [9663415.001]
  • [Cites] Am J Gastroenterol. 1987 Sep;82(9):876-9 [2820222.001]
  • [Cites] Biol Pharm Bull. 2000 Mar;23(3):344-8 [10726891.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1204-11 [8201383.001]
  • [Cites] Cancer. 1975 Dec;36(6 Suppl):2413-7 [1212659.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Surg Gynecol Obstet. 1977 Mar;144(3):335-8 [190716.001]
  • [Cites] Oncology. 2000 May;58(4):293-9 [10838494.001]
  • [Cites] Cancer. 1980 Mar 1;45(5):866-9 [7260838.001]
  • [Cites] Jpn J Cancer Res. 1986 Jun;77(6):523-5 [3015851.001]
  • [Cites] Biol Pharm Bull. 2000 May;23(5):637-40 [10823679.001]
  • [Cites] Cancer Res. 1984 May;44(5):2115-21 [6324996.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(5):401-4 [1312908.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1586-94 [2477131.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):699-704 [10954453.001]
  • (PMID = 14739665.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational; 0 / Lipids; 0 / Organoplatinum Compounds; 780F0P8N4I / miriplatin
  •  go-up   go-down


6. Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Ørum H, Elmén J, Seidah NG, Straarup EM: A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One; 2010 May 17;5(5):e10682
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
  • BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important factor in the etiology of familial hypercholesterolemia (FH) and is also an attractive therapeutic target to reduce low density lipoprotein (LDL) cholesterol.
  • METHODOLOGY/PRINCIPAL FINDINGS: The present study presents the first evidence for the efficacy of a locked nucleic acid (LNA) antisense oligonucleotide (LNA ASO) that targets both human and mouse PCSK9.
  • The major significance and take home message of this work is the development of a novel and promising approach for human therapeutic intervention of the PCSK9 pathway and hence for reducing some of the cardiovascular risk factors associated with the metabolic syndrome.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2006 Mar;78(3):410-22 [16465619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5374-9 [15805190.001]
  • [Cites] Hum Mol Genet. 2006 May 1;15(9):1551-8 [16571601.001]
  • [Cites] Am J Hum Genet. 2006 Sep;79(3):514-23 [16909389.001]
  • [Cites] J Lipid Res. 2007 Apr;48(4):763-7 [17242417.001]
  • [Cites] Traffic. 2007 Jun;8(6):718-32 [17461796.001]
  • [Cites] Atherosclerosis. 2007 Aug;193(2):445-8 [16989838.001]
  • [Cites] J Biol Chem. 2008 Jan 25;283(4):2363-72 [18039658.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1820-5 [18250299.001]
  • [Cites] Nucleic Acids Res. 2008 Mar;36(4):1153-62 [18158304.001]
  • [Cites] Nature. 2008 Apr 17;452(7189):896-9 [18368051.001]
  • [Cites] Hepatology. 2008 Aug;48(2):646-54 [18666258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11915-20 [18695239.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13045-50 [18753623.001]
  • [Cites] Expert Opin Ther Targets. 2009 Jan;13(1):19-28 [19063703.001]
  • [Cites] J Lipid Res. 2009 Apr;50 Suppl:S172-7 [19020338.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9820-5 [19443683.001]
  • [Cites] J Biol Chem. 2009 Oct 16;284(42):28856-64 [19635789.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2191-7 [19762784.001]
  • [Cites] J Lipid Res. 2010 Jan;51(1):140-9 [19571328.001]
  • [Cites] Nucleic Acids Res. 2010 Jan;38(1):e3 [19854938.001]
  • [Cites] Science. 2010 Jan 8;327(5962):198-201 [19965718.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):928-33 [12552133.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):154-6 [12730697.001]
  • [Cites] Hum Genet. 2004 Mar;114(4):349-53 [14727179.001]
  • [Cites] Clin Genet. 2004 May;65(5):419-22 [15099351.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100-5 [15118091.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1454-9 [15178557.001]
  • [Cites] J Immunol Methods. 1997 May 26;204(2):205-8 [9212838.001]
  • [Cites] J Immunol Methods. 1998 Apr 15;213(2):157-67 [9692848.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48865-75 [15358785.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2654-60 [16224054.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50630-8 [15385538.001]
  • [Cites] Nat Genet. 2005 Feb;37(2):161-5 [15654334.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2069-74 [15677715.001]
  • [Cites] Curr Opin Lipidol. 2005 Apr;16(2):167-72 [15767856.001]
  • [Cites] N Engl J Med. 2006 Mar 23;354(12):1264-72 [16554528.001]
  • (PMID = 20498851.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / CTP 82946; Canada / Canadian Institutes of Health Research / / MOP 36496
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotides; 0 / Oligonucleotides, Antisense; 0 / RNA, Messenger; 0 / Receptors, LDL; 0 / locked nucleic acid; EC 3.4.- / Proprotein Convertases; EC 3.4.21.- / PCSK9 protein, human; EC 3.4.21.- / Pcsk9 protein, mouse; EC 3.4.21.- / Serine Endopeptidases
  • [Other-IDs] NLM/ PMC2871785
  •  go-up   go-down


7. Grebely J, Raffa JD, Meagher C, Duncan F, Genoway KA, Khara M, McLean M, Mead A, Viljoen M, DeVlaming S, Fraser C, Conway B: Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol; 2007 Sep;22(9):1519-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users.
  • BACKGROUND AND AIM: There are few studies investigating the treatment of hepatitis C virus (HCV) infection in current and former drug users.
  • With this in mind, we sought to evaluate the antiviral efficacy of interferon alpha-2b (IFN alpha-2b) or pegylated-interferon alpha-2b (PEG-IFN alpha-2b) and ribavirin (RBV) in injection drug users (IDU) enrolled in a directly observed therapy (DOT) program, as measured by sustained virologic response (SVR).
  • Only 14 discontinued therapy, 5 due to toxicity, 6 due to illicit drug use and 3 did not achieve an early virologic response.
  • There was no significant difference in response rates among those with >6 (50%) or <or=6 months (64%) drug abstinence (P = 0.51) or among those with (53%) and without (57%) intercurrent drug use (P = 0.99); however, frequent users (n = 9) had a decreased SVR (22%) when compared with occasional users (n = 10, 80%, P = 0.12).
  • [MeSH-major] Hepatitis C / drug therapy. Hepatitis C / transmission. Substance Abuse, Intravenous
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Antiviral Agents / therapeutic use. Biomarkers / blood. British Columbia. Female. Genotype. Hepacivirus / genetics. Humans. Interferon-alpha / therapeutic use. Male. Polyethylene Glycols. Recombinant Proteins

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645460.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Biomarkers; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 99210-65-8 / interferon alfa-2b; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


8. Zaman F, Ye G, Abreo KD, Latif S, Zibari GB: Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure. Clin Transplant; 2003 Oct;17(5):461-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although many of its adverse effects are well recognized, TMP-SMZ related hepatotoxicity is considered rare and is usually characterized by cholestasis or mixed hepatocellular-holestatic reactions.
  • In this study, we describe the case of a previously healthy young man with acute fulminant liver failure caused by TMP-SMZ.
  • The patient presented with complaints of 'flu-like' symptoms with myalgia and fever after taking TMP-SMZ for 7 d for otitis externa.
  • [MeSH-major] Anti-Infective Agents / adverse effects. Liver Failure / chemically induced. Liver Transplantation. Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects


9. Tantawy AA: Molluscicidal effect of fenitrothion and anilofos on Lymnaea natalensis and Biomphalaria alexandrina snails and on the free larval stages of Schistosoma mansoni. J Egypt Soc Parasitol; 2006 Aug;36(2):629-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The LC10 & LC90 of fenitrothion was 0.12 & 0.21 ppm for L. nalalensis and 0.17 & .26 ppm for B. alexandrina, respectively.
  • The results showed that fenitrothion was more toxic to the free larval stages of S. mansoni than to their snails.
  • The results showed a significant reduction in total protein of treated snails when compared with controls in haemolymph while there was an increase of protein contents of the tissue.
  • ALT enzyme activity in haemolymph of experimental groups was higher than controls while its activity in tissue was lower.
  • AST enzyme activity was higher in haemolymph and tissue of experimental groups than in controls.
  • [MeSH-major] Biomphalaria / drug effects. Fenitrothion / pharmacology. Lymnaea / drug effects. Molluscacides / pharmacology. Organophosphorus Compounds / pharmacology. Schistosoma mansoni / drug effects
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Lethal Dose 50. Life Cycle Stages. Schistosomiasis mansoni / prevention & control. Schistosomiasis mansoni / transmission

  • Hazardous Substances Data Bank. FENITROTHION .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927873.001).
  • [ISSN] 1110-0583
  • [Journal-full-title] Journal of the Egyptian Society of Parasitology
  • [ISO-abbreviation] J Egypt Soc Parasitol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Molluscacides; 0 / Organophosphorus Compounds; 0 / anilofos; W8M4X3Y7ZY / Fenitrothion
  •  go-up   go-down


10. Adedapo AA, Adegbayibi AY, Emikpe BO: Some clinico-pathological changes associated with the aqueous extract of the leaves of Phyllanthus amarus in rats. Phytother Res; 2005 Nov;19(11):971-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The animals were divided into four groups of eight animals per group.
  • Histopathologically, there were cases of protein casts in the kidney tubules with tubular nephrosis, foci of lymphocytic infiltration at the portal areas of the liver as well as marked testicular degeneration with severe disorganization of seminiferous tubules, which were devoid of spermatic cells.
  • A reduction in the weight of the experimental animals was also noted in this study.
  • [MeSH-minor] Animals. Blood Cell Count. Blood Chemical Analysis. Body Weight / drug effects. Hematocrit. Kidney / drug effects. Kidney / pathology. Liver / drug effects. Liver / pathology. Male. Plant Extracts / toxicity. Plant Leaves / toxicity. Rats. Rats, Sprague-Dawley. Testis / drug effects. Testis / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16317655.001).
  • [ISSN] 0951-418X
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Plant Extracts
  •  go-up   go-down


11. Yang HY, Li J, Yi M: [Study on chronical hepatitis B with treatment of integrative traditional Chinese and Western medicine]. Zhongguo Zhong Yao Za Zhi; 2006 Aug;31(15):1277-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on chronical hepatitis B with treatment of integrative traditional Chinese and Western medicine].
  • OBJECTIVE: To study curative effect of chronical hepatitis B with treatment of integrative traditional Chinese and western medicine.
  • The first group treated by traditional Chinese medicine (TCM)-Fufang Huangqi granule and the second treated by intergrative traditional Chinese and western medicine (ICWM)-Fufang Huangqi granule and lamivudine for at least 24 weeks.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Hepatitis B, Chronic / drug therapy. Lamivudine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Albumins / metabolism. Anti-HIV Agents / therapeutic use. Astragalus membranaceus / chemistry. DNA, Viral / blood. Drug Combinations. Drug Synergism. Female. Hepatitis B e Antigens / blood. Hepatitis B virus / genetics. Humans. Male. Middle Aged. Plants, Medicinal / chemistry

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048576.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Albumins; 0 / Anti-HIV Agents; 0 / DNA, Viral; 0 / Drug Combinations; 0 / Drugs, Chinese Herbal; 0 / Hepatitis B e Antigens; 2T8Q726O95 / Lamivudine
  •  go-up   go-down


12. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD: Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology; 2002 Jul;36(1):186-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis B e Antigens / blood. Hepatitis B, Chronic / drug therapy. Lamivudine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Alanine Transaminase / blood. DNA, Viral / blood. Drug Therapy, Combination. Ethnic Groups. Female. Hepatitis B Antibodies / blood. Hepatitis B virus / genetics. Humans. Interferon-alpha / therapeutic use. Interferons / therapeutic use. Male. Middle Aged. Placebos. Recombinant Proteins. Reverse Transcriptase Inhibitors / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12085364.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR 01066
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Hepatitis B Antibodies; 0 / Hepatitis B e Antigens; 0 / Interferon-alpha; 0 / Placebos; 0 / Recombinant Proteins; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine; 9008-11-1 / Interferons; 99210-65-8 / interferon alfa-2b; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


13. Hu KQ, Tiyyagura L, Kanel G, Redeker AG: Acute hepatitis induced by bupropion. Dig Dis Sci; 2000 Sep;45(9):1872-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As an antidepressant, bupropion is considered to be a safe agent that usually causes infrequent and mild increase of serum liver enzymes.
  • [MeSH-major] Antidepressive Agents, Second-Generation / adverse effects. Bupropion / adverse effects. Chemical and Drug Induced Liver Injury / etiology. Dopamine Uptake Inhibitors / adverse effects

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. Bupropion .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Psychiatry. 1991 Nov;52(11):450-6 [1744061.001]
  • [Cites] Psychiatr Clin North Am. 1996 Sep;19(3):495-514 [8856814.001]
  • [Cites] J Clin Psychiatry. 1994 Sep;55(9):391-3 [7929019.001]
  • [Cites] J Clin Psychiatry. 1983 May;44(5 Pt 2):60-2 [6406465.001]
  • [Cites] J Clin Psychiatry. 1995;56 Suppl 2:3-9 [7844104.001]
  • [Cites] J Clin Psychiatry. 1983 May;44(5 Pt 2):191-6 [6406456.001]
  • [Cites] J Clin Psychopharmacol. 1993 Oct;13(5):364-5 [8227497.001]
  • [Cites] Am J Emerg Med. 1994 Jan;12(1):43-5 [8285970.001]
  • [Cites] Hepatology. 1997 Sep;26(3):664-9 [9303497.001]
  • (PMID = 11052334.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; 0 / Dopamine Uptake Inhibitors; 01ZG3TPX31 / Bupropion
  •  go-up   go-down


14. Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K, Ishikawa H, Masaki N, Seriu T, Omata M: Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol; 2010 Jun;52(6):791-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antiviral Agents / administration & dosage. Asian Continental Ancestry Group. Drug Resistance, Viral. Guanine / analogs & derivatives. Hepatitis B, Chronic / drug therapy
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Biopsy. Cohort Studies. Drug Administration Schedule. Female. Hepatitis B Antibodies / blood. Hepatitis B e Antigens / immunology. Humans. Liver / metabolism. Liver / pathology. Liver / virology. Male. Middle Aged. Nucleosides. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier B.V.
  • (PMID = 20409606.001).
  • [ISSN] 1600-0641
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis B Antibodies; 0 / Hepatitis B e Antigens; 0 / Nucleosides; 5968Y6H45M / entecavir; 5Z93L87A1R / Guanine; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


15. Okamoto T, Masuda Y, Kawasaki T: Prevention of concanavalin A-induced mice hepatitis by molsidomine. Int J Mol Med; 2001 Mar;7(3):307-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Concanavalin A / toxicity. Drug-Induced Liver Injury / prevention & control. Molsidomine / therapeutic use. Vasodilator Agents / therapeutic use
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Antibodies / immunology. Antibodies / metabolism. Antigens, CD95 / immunology. Disease Models, Animal. Female. Mice. Mice, Inbred BALB C

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11179512.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD95; 0 / Vasodilator Agents; 11028-71-0 / Concanavalin A; D46583G77X / Molsidomine; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


16. Latina MA, de Leon JM: Selective laser trabeculoplasty. Ophthalmol Clin North Am; 2005 Sep;18(3):409-19, vi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Selective laser trabeculoplasty (SLT) has been shown to be safe, well tolerated, and effective in intraocular pressure (IOP) reduction as therapy in several forms of open-angle glaucoma.
  • Furthermore, SLT can be considered as a primary treatment option in patients who cannot tolerate or who are noncompliant with their glaucoma medications, without interfering with the success of future surgery.

  • MedlinePlus Health Information. consumer health - Glaucoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054998.001).
  • [ISSN] 0896-1549
  • [Journal-full-title] Ophthalmology clinics of North America
  • [ISO-abbreviation] Ophthalmol Clin North Am
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


17. Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ: Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat; 2005 Jul;12(4):398-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
  • YMDD mutation at rtL180M and rtM204V/I measured by restriction digest of amplified products.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis B virus / genetics. Hepatitis B, Chronic / drug therapy. Lamivudine / therapeutic use
  • [MeSH-minor] Alanine Transaminase / blood. Amino Acid Substitution. Canada. DNA, Viral. Drug Resistance, Viral. Female. Genotype. Hepatitis B e Antigens / blood. Humans. Liver Cirrhosis / virology. Male. Middle Aged. Mutation, Missense. Retrospective Studies. Sequence Analysis, DNA. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985011.001).
  • [ISSN] 1352-0504
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Hepatitis B e Antigens; 2T8Q726O95 / Lamivudine; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


18. Llanos L, Moreu R, Ortin T, Peiró AM, Pascual S, Bellot P, Barquero C, Francés R, Such J, Pérez-Mateo M, Horga JF, Zapater P: The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports. Aliment Pharmacol Ther; 2010 Jun;31(12):1337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports.
  • BACKGROUND: Drug-induced liver injury (DILI) profile in most drugs' available information is based on both the incidence of alanine aminotansferase (ALT) elevations in clinical trials and published case reports.
  • METHODS: Hepatotoxic drugs were identified from product labelling and classified in high-medium risk (Black Box Warning or Precautions section) or low risk (a statement in the Adverse Reactions section).
  • Incidence of ALT elevations (> or = 3 x ULN) for drug (I(D)) and placebo (I(C)) treated patients in premarketing clinical trials and DILI published case reports were retrieved from product labelling and MEDLINE.
  • The high-medium-risk drugs' median I(D) was significantly higher compared with low-risk drugs (17/1000 vs. 10/1000; P = 0.046).
  • Chi-squared test, absolute difference and odds ratio comparing I(D) and I(C) identified 35%, 51% and 77% of high-medium-risk drugs respectively.
  • Less number of case reports were associated with low- than high-medium-risk drugs (1 vs. 7; P = 0.001).
  • [MeSH-major] Alanine Transaminase / blood. Drug-Induced Liver Injury / enzymology
  • [MeSH-minor] Biomarkers / blood. Clinical Trials as Topic. Drug Labeling. Humans. Incidence. Periodicals as Topic. Product Surveillance, Postmarketing. Publication Bias. Safety-Based Drug Withdrawals

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20331578.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


19. Gravato C, Santos MA: Juvenile sea bass liver biotransformation induction and erythrocytic genotoxic responses to resin acids. Ecotoxicol Environ Saf; 2002 Jul;52(3):238-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile sea bass liver biotransformation induction and erythrocytic genotoxic responses to resin acids.
  • Liver damage was assessed as liver alanine aminotransferase activity (ALT) and liver somatic index (LSI) was used as a general health indicator.
  • Therefore, the comparative analysis of the two resin acids genotoxic effects, measured as EMN and ENA, indicated that DHAA is more genotoxic than AA.
  • [MeSH-minor] Animals. Biotransformation. DNA Damage. Dose-Response Relationship, Drug. Liver / enzymology. Liver / pathology. Micronucleus Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12297086.001).
  • [ISSN] 0147-6513
  • [Journal-full-title] Ecotoxicology and environmental safety
  • [ISO-abbreviation] Ecotoxicol. Environ. Saf.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diterpenes; 0 / Diterpenes, Abietane; 0 / Free Radical Scavengers; 0 / Phenanthrenes; 0S5XP6S3AU / dehydroabietic acid; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; V3DHX33184 / abietic acid
  •  go-up   go-down


20. Rong X, Kim MS, Su N, Wen S, Matsuo Y, Yamahara J, Murray M, Li Y: An aqueous extract of Salacia oblonga root, a herb-derived peroxisome proliferator-activated receptor-alpha activator, by oral gavage over 28 days induces gender-dependent hepatic hypertrophy in rats. Food Chem Toxicol; 2008 Jun;46(6):2165-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An aqueous extract of Salacia oblonga root (SOW) is an Ayurvedic medicine with anti-diabetic and anti-obesity properties.
  • [MeSH-minor] Acyl Coenzyme A / biosynthesis. Animals. Body Weight / drug effects. Cell Line, Tumor. Data Interpretation, Statistical. Fatty Liver / chemically induced. Fatty Liver / pathology. Female. Gene Expression / drug effects. Humans. Hypertrophy. Liver Neoplasms / pathology. Male. Plant Extracts / toxicity. Plant Roots / chemistry. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Rats. Rats, Sprague-Dawley. Sex Characteristics. Weight Gain / drug effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18397819.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acyl Coenzyme A; 0 / PPAR alpha; 0 / Plant Extracts; 0 / RNA, Messenger
  •  go-up   go-down


21. Tang XH, Gao J, Fang F, Chen J, Xu LZ, Zhao XN, Xu Q: Hepatoprotection of oleanolic acid is related to its inhibition on mitochondrial permeability transition. Am J Chin Med; 2005;33(4):627-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Drug-Induced Liver Injury / drug therapy. Mitochondria, Liver / drug effects. Mitochondria, Liver / metabolism. Mitochondrial Swelling / drug effects. Oleanolic Acid / pharmacology
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Calcium / pharmacokinetics. Carbon Tetrachloride. In Vitro Techniques. Male. Membrane Potentials / drug effects. Mice. Mice, Inbred ICR

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. CARBON TETRACHLORIDE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173536.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 6SMK8R7TGJ / Oleanolic Acid; CL2T97X0V0 / Carbon Tetrachloride; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; SY7Q814VUP / Calcium
  •  go-up   go-down


22. Kryczka W, Brojer E, Zarebska-Michaluk D, Medyńska J, Urbaniak A: Factors influencing natural history of chronic hepatitis C. Med Sci Monit; 2001 May;7 Suppl 1:212-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HbsAg and HIV-positive, as well as patients taking drugs were excluded from the study.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12211722.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


23. Kajikawa S, Harada T, Kawashima A, Imada K, Mizuguchi K: Suppression of hepatic fat accumulation by highly purified eicosapentaenoic acid prevents the progression of d-galactosamine-induced hepatitis in mice fed with a high-fat/high-sucrose diet. Biochim Biophys Acta; 2009 Apr;1791(4):281-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BALB/cA mice were fed with a standard diet (STD) or a high-fat and high-sucrose diet (HFHSD) for 14 days followed by intraperitoneal injection of d-galactosamine (DGalN) or vehicle.
  • After 20-21 h, plasma and liver tissue were collected and analyzed.
  • This exacerbation by the HFHSD was also observed in the plasma soluble tumor necrosis factor receptor (sTNFR) levels, and hepatic levels of reactive oxygen species (ROS) and the fibrogenic gene expression, such as tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), connective tissue growth factor (CTGF) and osteopontin (OPN) in HFHSD-fed mice treated with DGalN.
  • [MeSH-major] Dietary Fats / administration & dosage. Dietary Sucrose / administration & dosage. Eicosapentaenoic Acid / pharmacology. Galactosamine / toxicity. Hepatitis / prevention & control. Liver / drug effects
  • [MeSH-minor] Adiponectin / blood. Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Connective Tissue Growth Factor / blood. Gene Expression / drug effects. Male. Mice. Mice, Inbred BALB C. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reactive Oxygen Species / metabolism. Receptors, Tumor Necrosis Factor / blood. Reverse Transcriptase Polymerase Chain Reaction. Sterol Regulatory Element Binding Protein 1 / metabolism. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Hepatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416647.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Dietary Fats; 0 / Dietary Sucrose; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0 / Receptors, Tumor Necrosis Factor; 0 / Sterol Regulatory Element Binding Protein 1; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Triglycerides; 139568-91-5 / Connective Tissue Growth Factor; 7535-00-4 / Galactosamine; AAN7QOV9EA / Eicosapentaenoic Acid; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


24. Nishiguchi S, Kaneshiro S, Tanaka M, Enomoto M, Akihiro T, Habu D, Takeda T, Fujino K, Tanaka T, Yano Y, Shiomi S: Association of HLA alleles with response (especially biochemical response) to interferon therapy in Japanese patients with chronic hepatitis C. J Interferon Cytokine Res; 2003 Mar;23(3):135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Alleles. HLA Antigens / genetics. Hepatitis C, Chronic / drug therapy. Hepatitis C, Chronic / genetics. Interferons / therapeutic use
  • [MeSH-minor] Antiviral Agents / administration & dosage. Antiviral Agents / therapeutic use. Biomarkers / blood. Disease Progression. Dose-Response Relationship, Drug. Female. Fibrosis / complications. Fibrosis / drug therapy. Genotype. HLA-A Antigens / genetics. HLA-DQ Antigens / genetics. HLA-DR Antigens / genetics. Hepacivirus / drug effects. Hepacivirus / genetics. Hepacivirus / isolation & purification. Histocompatibility Testing. Humans. Inflammation / drug therapy. Inflammation / etiology. Inflammation / pathology. Interferon-alpha / administration & dosage. Interferon-alpha / therapeutic use. Interferon-beta / administration & dosage. Interferon-beta / therapeutic use. Japan. Male. Middle Aged. RNA, Viral / blood. RNA, Viral / drug effects. Recombinant Proteins. Severity of Illness Index. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12716485.001).
  • [ISSN] 1079-9907
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Biomarkers; 0 / HLA Antigens; 0 / HLA-A Antigens; 0 / HLA-DQ Antigens; 0 / HLA-DR Antigens; 0 / Interferon-alpha; 0 / RNA, Viral; 0 / Recombinant Proteins; 77238-31-4 / Interferon-beta; 9008-11-1 / Interferons; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


25. Ito Y, Abril ER, Bethea NW, McCuskey RS: Role of nitric oxide in hepatic microvascular injury elicited by acetaminophen in mice. Am J Physiol Gastrointest Liver Physiol; 2004 Jan;286(1):G60-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A selective inducible NO synthase (iNOS) inhibitor,l-N6-(1-iminoethyl)-lysine (L-NIL), or a nonselective NOS inhibitor, NG-nitro-l-arginine methyl ester (L-NAME), was intraperitoneally administered to animals 10 min before APAP gavage.
  • In contrast, NO derived from constitutive isoforms of NOS exerts a protective role in liver microcirculation against APAP intoxication and thereby minimizes liver injury.
  • [MeSH-major] Acetaminophen / toxicity. Analgesics, Non-Narcotic / toxicity. Drug-Induced Liver Injury / pathology. Nitric Oxide / physiology. Tyrosine / analogs & derivatives
  • [MeSH-minor] Alanine Transaminase / metabolism. Animals. Capillaries / pathology. Enzyme Inhibitors / pharmacology. Glutathione / metabolism. Immunohistochemistry. Kupffer Cells / drug effects. Kupffer Cells / ultrastructure. Liver / metabolism. Liver / pathology. Male. Mice. Mice, Inbred C57BL. NG-Nitroarginine Methyl Ester / pharmacology. Nitric Oxide Donors / metabolism. Nitric Oxide Synthase / antagonists & inhibitors. Nitric Oxide Synthase Type II. Nitric Oxide Synthase Type III. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12969830.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / R01-AA-12436
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Enzyme Inhibitors; 0 / Nitric Oxide Donors; 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 362O9ITL9D / Acetaminophen; 42HK56048U / Tyrosine; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 1.14.13.39 / Nos2 protein, mouse; EC 1.14.13.39 / Nos3 protein, mouse; EC 2.6.1.2 / Alanine Transaminase; GAN16C9B8O / Glutathione; V55S2QJN2X / NG-Nitroarginine Methyl Ester
  •  go-up   go-down


26. Yuan HD, Jin GZ, Piao GC: Hepatoprotective effects of an active part from Artemisia sacrorum Ledeb. against acetaminophen-induced toxicity in mice. J Ethnopharmacol; 2010 Feb 3;127(2):528-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS OF STUDY: Although Artemisia sacrorum Ledeb. (Compositae) has long been used as one kind of oriental folk medicine to treat some liver diseases, the underlying mechanism(s) by which these effects are induced remains to be defined.
  • MATERIALS AND METHODS: The levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and tumor necrosis factor-alpha (TNF-alpha) levels in mouse sera, and glutathione (GSH), malondialdehyde (MDA) in mouse liver tissues were measured.
  • [MeSH-major] Acetaminophen / toxicity. Artemisia. Drug-Induced Liver Injury / prevention & control. Plant Extracts / therapeutic use
  • [MeSH-minor] Animals. Liver Function Tests / methods. Male. Mice. Mice, Inbred C57BL. Plant Components, Aerial

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • [ErratumIn] J Ethnopharmacol. 2010 May 27;129(2):283
  • (PMID = 19833181.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Plant Extracts; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


27. Torezan-Filho MA, Alves VA, Neto CA, Fernandes HS, Strauss E: Clinical significance of elevated alanine aminotransferase in blood donors: a follow-up study. Liver Int; 2004 Dec;24(6):575-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Alcoholism, obesity, drug-induced liver disease, diabetes, hemochromatosis and alpha 1-anti-trypsin deficiency were investigated in 119 subjects (113 males, six females, aged 33.4+/-8.4 years) who were hepatitis B surface antigen/anti-hepatitis C virus negative and had been rejected as blood donors as a result of elevated ALT (>1.5 times the upper normal limit (UNL) in two determinations).

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15566507.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


28. Andries S, Casamayou L, Sempoux C, Burlet M, Reding R, Bernard Otte J, Buts JP, Sokal E: Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation; 2001 Jul 27;72(2):267-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine.
  • Our aim was to evaluate the incidence in a series of 471 pediatric liver transplant recipients.
  • Thirty-one patients had graft dysfunction, related to well-explained posttransplant causes, among which 7 had similar low levels of autoantibodies.
  • [MeSH-major] Azathioprine / therapeutic use. Hepatitis, Autoimmune / epidemiology. Immunosuppressive Agents / therapeutic use. Liver Transplantation / immunology. Postoperative Complications / epidemiology
  • [MeSH-minor] Adolescent. Alanine Transaminase / blood. Aspartate Aminotransferases / blood. Child. Child, Preschool. Cyclosporine / therapeutic use. Drug Therapy, Combination. Female. Humans. Liver Function Tests. Male. Prednisone / therapeutic use. Retrospective Studies. Tacrolimus / therapeutic use


29. Liberek A, Łuczak G, Korzon M, Szlagatys-Sidorkiewicz A, Bako W, Góra-Gebka M, Rytlewska M, Sikorska-Wiśniewska G: Tolerance of interferon-alpha therapy in children with chronic hepatitis B. J Paediatr Child Health; 2004 May-Jun;40(5-6):265-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The most frequent side-effects of IFN-alpha therapy were fever, flu-like symptoms, and headaches.
  • CONCLUSION: The side-effects of the IFN-alpha therapy in children such as fever, flu-like symptoms and bone marrow suppression are common, but transient and mild.
  • [MeSH-major] Antiviral Agents / adverse effects. Hepatitis B, Chronic / drug therapy. Interferon-alpha / adverse effects
  • [MeSH-minor] Adolescent. Alanine Transaminase / blood. Appetite / drug effects. Blood Platelets / drug effects. Child. Child, Preschool. Female. Fever / chemically induced. Headache / chemically induced. Humans. Infant. Leukocytes / drug effects. Male. Prospective Studies. Statistics as Topic. Time Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15151579.001).
  • [ISSN] 1034-4810
  • [Journal-full-title] Journal of paediatrics and child health
  • [ISO-abbreviation] J Paediatr Child Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


30. Izeboud CA, Hoebe KH, Grootendorst AF, Nijmeijer SM, van Miert AS, Witkamp RR, Rodenburg RJ: Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation. Inflamm Res; 2004 Mar;53(3):93-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver histological examination was performed to look for changes in tissue morphology.
  • Clenbuterol minimized LPS-induced liver damage, as represented by significantly lowered concentrations of several parameters for liver-failure (AST, ALT, Bilirubin), and improved hepatic tissue morphology.
  • CONCLUSIONS: The results indicate that a selective beta(2)-AR agonist might be used as an additional therapeutic agent in the clinic for the treatment of (acute) systemic inflammatory disorders in order to reduce or prevent subsequent liver failure.
  • [MeSH-major] Adrenergic beta-Agonists / pharmacology. Clenbuterol / pharmacology. Endotoxins / pharmacology. Liver / drug effects. Liver / pathology. Liver Failure / prevention & control
  • [MeSH-minor] Adrenergic beta-Antagonists / pharmacology. Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Inflammation / prevention & control. Interleukin-1 / antagonists & inhibitors. Interleukin-1 / blood. Interleukin-10 / antagonists & inhibitors. Interleukin-10 / blood. Interleukin-6 / antagonists & inhibitors. Interleukin-6 / blood. Lipopolysaccharides / antagonists & inhibitors. Lipopolysaccharides / pharmacology. Male. Osmolar Concentration. Propranolol / pharmacology. Rats. Rats, Wistar. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Tumor Necrosis Factor-alpha / metabolism

  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15021963.001).
  • [ISSN] 1023-3830
  • [Journal-full-title] Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  • [ISO-abbreviation] Inflamm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Adrenergic beta-Antagonists; 0 / Endotoxins; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Lipopolysaccharides; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 9Y8NXQ24VQ / Propranolol; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; XTZ6AXU7KN / Clenbuterol
  •  go-up   go-down


31. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, Feinstone SM: Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol; 2002 Jul;76(13):6586-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All animals were challenged by reverse titration with decreasing dilutions of plasma and became serum RNA positive following challenge.
  • Ch1605 displayed a typical disease profile for a chimpanzee.
  • A comparison of intrahepatic cytokine levels in Ch1552 and Ch1605 showed greater and earlier gamma interferon (IFN-gamma) and tumor necrosis factor alpha responses in the previously infected animal, responses that were 30-fold greater than baseline responses at week 4 p.i. for IFN-gamma in Ch1552 compared to 12-fold in Ch1605 at week 10 p.i.
  • These data indicate (i) that clonal HCV generated from an infectious RNA transcript will lead to a typical HCV infection in naïve chimpanzees, (ii) that there are memory immune responses in recovered chimpanzees that control HCV infection upon rechallenge, and (iii) that these responses seem to be T-cell mediated, as none of the animals had detectable antibody against the HCV envelope glycoproteins.
  • These observations have encouraging implications for the development of a vaccine for HCV.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7792-6 [7519785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1294-8 [7509068.001]
  • [Cites] J Infect Dis. 1996 Apr;173(4):822-8 [8603959.001]
  • [Cites] J Virol. 1996 May;70(5):3307-12 [8627816.001]
  • [Cites] J Virol. 1996 Jun;70(6):3363-71 [8648666.001]
  • [Cites] J Virol. 1997 Aug;71(8):6011-9 [9223492.001]
  • [Cites] Science. 1997 Jul 25;277(5325):570-4 [9228008.001]
  • [Cites] Springer Semin Immunopathol. 1997;19(1):85-98 [9266633.001]
  • [Cites] J Virol. 1998 Apr;72(4):2589-99 [9525575.001]
  • [Cites] Arch Virol. 1998;143(12):2493-503 [9930205.001]
  • [Cites] J Virol. 1999 Apr;73(4):3317-25 [10074186.001]
  • [Cites] Immunity. 1999 Apr;10(4):439-49 [10229187.001]
  • [Cites] J Infect Dis. 1999 Oct;180(4):987-91 [10479122.001]
  • [Cites] J Virol. 2000 Feb;74(4):2046-51 [10644379.001]
  • [Cites] J Exp Med. 2000 May 1;191(9):1499-512 [10790425.001]
  • [Cites] Nat Med. 2000 May;6(5):578-82 [10802716.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1528-36 [10823750.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1479-87 [11391537.001]
  • [Cites] J Virol. 2001 Aug;75(15):7142-8 [11435595.001]
  • [Cites] J Infect Dis. 1981 Dec;144(6):588-98 [6799586.001]
  • [Cites] Science. 1989 Apr 21;244(4902):359-62 [2523562.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6547-9 [2168552.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1711-5 [1705704.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5547-51 [1648221.001]
  • [Cites] J Infect Dis. 1992 Mar;165(3):438-43 [1538149.001]
  • [Cites] Science. 1992 Oct 2;258(5079):135-40 [1279801.001]
  • [Cites] N Engl J Med. 1992 Dec 31;327(27):1899-905 [1280771.001]
  • [Cites] J Virol. 1993 Mar;67(3):1385-95 [7679746.001]
  • [Cites] J Infect Dis. 1993 Mar;167(3):726-30 [8382721.001]
  • [Cites] Lancet. 1994 Feb 12;343(8894):388-90 [7905553.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2755-9 [7708719.001]
  • (PMID = 12050371.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085883; United States / NCI NIH HHS / CA / CA 85883
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Hepatitis C Antibodies; 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC136282
  •  go-up   go-down


32. Lu W, Li YH, Yu ZJ, He XF, Chen Y, Zhao JB, Zhu ZY: A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. Hepatogastroenterology; 2007 Jul-Aug;54(77):1499-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma.
  • BACKGROUND/AIMS: To study liver function damage after transcatheter arterial chemoembolization (TACE) with use of low-dose versus conventional-dose anticancer drugs in patients with hepatocellular carcinoma (HCC).
  • Patients in group A (n=52) received low-dose anticancer drugs: mitomycin C (MMC) 2-8 mg, epirubicin (EPI) 5-10 mg and carboplatin (CBP) 100mg were used.
  • Patients in group B (n=60) were given conventional-dose of anticancer drugs (MMC 10 mg, EPI 40 mg, CBP 300 mg).
  • Lipiodol-anticancer drugs emulsion was injected into the feeding arteries of tumors followed by gelatin sponge (GS) or polyvinyl alcohol (PVA) particles embolization.
  • RESULTS: In both groups, TBIL, ALT, and Child-Pugh scores increased (P < 0.001 or P < 0.05) and ALB decreased (P < 0.001 or P < 0.01) three days and one wk after TACE.
  • CONCLUSIONS: Superselective TACE with use of low-dose anticancer drugs induces transient impairment in liver function, but use of conventional-dose anticancer drugs can cause lasting, more serious worsening of liver function.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Epirubicin / administration & dosage. Liver Neoplasms / therapy. Mitomycin / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708284.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; BG3F62OND5 / Carboplatin
  •  go-up   go-down


33. Montané J, Marco I, López-Olvera J, Perpiñán D, Manteca X, Lavín S: Effects of acepromazine on capture stress in roe deer (Capreolus capreolus). J Wildl Dis; 2003 Apr;39(2):375-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate effect of a short-acting neuroleptic (acepromazine) on capture stress response in roe deer (Capreolus capreolus).
  • Roe deer were divided into two groups: animals in the treatment group received an intramuscular injection of acepromazine (0.093 mg/kg +/- 0.003 SEM; n = 8) while animals in the control group (n = 8) did not receive tranquilizer.
  • Heart rate and body temperature, as well as hematologic and biochemical indicators of stress, were used to evaluate effect of the neuroleptic over 3 hr.
  • Comparisons of blood parameters revealed significantly lower red blood cell count (RBC), lymphocyte count, hemoglobin concentration, packed cell volume (PCV), and serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) activities in tranquilized animals compared with controls (at least P < 0.05).
  • A reduction in PCV, lymphocyte count, and serum cortisol concentrations (at least P < 0.05) and an increase in serum creatinine levels (P < 0.05) were recorded over time in control animals, while a reduction in RBC and hemoglobin concentration (at least P < 0.05) and an increase in serum urea concentrations (P < 0.05) over time were observed in the treated group.
  • [MeSH-major] Acepromazine / therapeutic use. Antipsychotic Agents / therapeutic use. Deer. Stress, Physiological / veterinary
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Body Temperature / drug effects. Creatine Kinase / blood. Creatinine / blood. Erythrocyte Count / veterinary. Female. Handling (Psychology). Heart Rate / drug effects. Hematocrit / veterinary. Hemoglobins / analysis. Hydrocortisone / blood. L-Lactate Dehydrogenase / blood. Lactic Acid / blood. Lymphocyte Count / veterinary. Male. Potassium / blood. Random Allocation. Restraint, Physical / veterinary. Transportation. Urea / blood

  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. UREA .
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12910765.001).
  • [ISSN] 0090-3558
  • [Journal-full-title] Journal of wildlife diseases
  • [ISO-abbreviation] J. Wildl. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Hemoglobins; 33X04XA5AT / Lactic Acid; 54EJ303F0R / Acepromazine; 8W8T17847W / Urea; AYI8EX34EU / Creatinine; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 2.7.3.2 / Creatine Kinase; RWP5GA015D / Potassium; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


34. Schiemann U, Glas J, Török P, Simperl C, Martin K, König A, Schmidt F, Schaefer M, Folwaczny C: Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. Digestion; 2003;68(1):1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of chronic active hepatitis C.
  • A response was defined as absence of HCV-RNA and normalization of S-ALT after 6 months of combination therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Promoter Regions, Genetic. Ribavirin / therapeutic use. Tumor Necrosis Factor-alpha / genetics
  • [MeSH-minor] Adult. Alleles. Case-Control Studies. Drug Therapy, Combination. Female. Genotype. Humans. Male. Polymorphism, Genetic. Recombinant Proteins

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12949432.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 47RRR83SK7 / interferon alfa-2a; 49717AWG6K / Ribavirin
  •  go-up   go-down


35. Wang M, Sakon M, Umeshita K, Okuyama M, Shiozaki K, Nagano H, Dohno K, Nakamori S, Monden M: Prednisolone suppresses ischemia-reperfusion injury of the rat liver by reducing cytokine production and calpain mu activation. J Hepatol; 2001 Feb;34(2):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Base Sequence. DNA Primers / genetics. Enzyme Activation / drug effects. Interleukin-1 / biosynthesis. Interleukin-1 / genetics. Male. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Rats, Wistar. Talin / metabolism. Tumor Necrosis Factor-alpha / biosynthesis. Tumor Necrosis Factor-alpha / genetics

  • Hazardous Substances Data Bank. PREDNISOLONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11281557.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA Primers; 0 / Interleukin-1; 0 / RNA, Messenger; 0 / Talin; 0 / Tumor Necrosis Factor-alpha; 9PHQ9Y1OLM / Prednisolone; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.4.22.- / Calpain
  •  go-up   go-down


36. Pereira C, Mapuskar K, Rao CV: Chronic toxicity of diethyl phthalate in male Wistar rats--a dose-response study. Regul Toxicol Pharmacol; 2006 Jul;45(2):169-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diethyl phthalate (DEP) is widely used in personal care products, plastics and medical devices at various concentrations, but its information is limited on its toxicity associated with exposure at high as well as low doses for a prolonged period.
  • After 5 months of treatment animals were sacrificed, enzymes and other biochemical parameters in the serum and liver were assessed.
  • Other biochemical parameters like glycogen, total cholesterol, total triglycerides and lipid peroxidation were also increased in the liver of all the three treated groups.
  • It is evident from this study that treatment with higher concentrations of DEP results in mitochondrial proliferation as well as accumulation of glycogen, cholesterol and triglycerides within the liver, but exposure to lower concentrations for longer periods results in increase in peroxisome numbers leading to severe hepatocellular changes which can be confirmed by significantly increased liver weights, elevated enzyme levels in the serum and liver and impaired metabolism of glycogen, cholesterol and triglyceride as well as altered liver histology.
  • [MeSH-major] Environmental Pollutants / toxicity. Liver / drug effects. Phthalic Acids / toxicity
  • [MeSH-minor] Acid Phosphatase / metabolism. Administration, Oral. Alanine Transaminase / metabolism. Animals. Cholesterol / metabolism. Dose-Response Relationship, Drug. Glycogen / metabolism. Lipid Peroxidation. Male. Mitochondria, Liver / ultrastructure. Organ Size. Rats. Rats, Wistar. Toxicity Tests, Chronic. Triglycerides / metabolism

  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. DIETHYL PHTHALATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750591.001).
  • [ISSN] 0273-2300
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Phthalic Acids; 0 / Triglycerides; 9005-79-2 / Glycogen; 97C5T2UQ7J / Cholesterol; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.2 / Acid Phosphatase; UF064M00AF / diethyl phthalate
  •  go-up   go-down


37. Babu ChK, Khanna SK, Das M: Safety evaluation studies on argemone oil through dietary exposure for 90days in rats. Food Chem Toxicol; 2006 Jul;44(7):1151-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Animals were given AO in diet at a dose of 0.001%, 0.01%, 0.1%, 0.5% and 1% daily for 90 days and the two control groups received the standard diet with and without 1% mustard oil.
  • A decrease in body weight gain (28-31%) was observed in 0.5% and 1% AO groups; while significant increases in relative lungs and liver weight was noticed in respective doses of 0.01% and 0.1% AO groups as well as in higher dosage animals.
  • Reduction in RBC count and hemoglobin content (p<0.05) was noticed in 0.01% and 0.1% AO exposed animals.
  • The levels of serum triglycerides and VLDL cholesterol were found to be enhanced (p<0.05) in AO treated (0.01-1.0%) animals.
  • None of the parameters were found to be affected in 0.001% AO treated animals.
  • [MeSH-minor] Animals. Blood Cell Count. Blood Proteins / analysis. Body Weight / drug effects. Diet. Eating / drug effects. Kidney / pathology. Lipids / blood. Liver / pathology. Liver Function Tests. Male. Myocardium / pathology. Organ Size / drug effects. Rats. Rats, Wistar. Seeds / chemistry. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554115.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Lipids; 0 / Plant Oils; 0 / argemone oil
  •  go-up   go-down


38. Ishikawa T, Soh N: [Evaluation of quality of life (QOL) and efficacy of drug therapy on nasal symptoms and QOL disturbances in the patients with Japanese Cedar Pollinosis during the season of 2003 in Kyushu and Okinawa districts]. Arerugi; 2004 Nov;53(11):1131-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of quality of life (QOL) and efficacy of drug therapy on nasal symptoms and QOL disturbances in the patients with Japanese Cedar Pollinosis during the season of 2003 in Kyushu and Okinawa districts].
  • AIM: The aim of the study is to investigate nasal symptom severity (NSS) and disturbance of quality of life (QOLD) of patients with Japanese Cedar Pollinosis (JCP) during the JC season of 2003, and to evaluate the efficacy of drug treatment on the NSS/QOLD by the data based on disease specific Japan Rhino-conjunctivitis Quality of Life Questionnaire (JRQLQ).
  • Degree of NSS/QOLD was scored as 1 to 4 in order (1 for a little and 4 for extremely severe or bothered respectively). (1) About 23% of 3173 subjects analyzed complained NSS score > or =3 and about 64% score > or =2.
  • About 10% complained QOLD score > or =3 and about 20-30% score > or =2. (2) Preventive effect of pre-seasonal medication was analyzed.
  • We evaluated the data from 583 patients (177 : received pre-seasonal medication and 406 : not received) who first answered questionnaire before peak of pollen dispersion as the effects on rising-up of symptoms in early stage of pollen scattering, and the data from 1223 patients (431 : received pre-seasonal medication and 792 : not received) who answered during the whole season as the effects on symptoms in whole season.
  • The results of the both analyses indicated that the pre-seasonal medication significantly reduced NSS/QOLD in early stage of pollen scattering as well as during whole season as a preventive effect. (3) Effect of drugs prescribed at the first reply to the questionnaire was analyzed in 582 patients who answered the questionnaire twice before and after the peak of JC pollen scattering (February 28th), with at least 7 days intervals between 2 answers.
  • When a proper designate of prescribed drug was not specified, results of second answer from 582 patients showed significant reduction of NSS/ QOLD score (p<0.001). (4) Single drug which effect was able to be evaluated was anti-allergic drug (mainly second generation of anti histamine: aH) in 81 cases, or anti-leukotriene (aLT) in 25 cases.
  • Although the both drugs were effective, the comparison analysis of effectiveness of 2 drugs indicated that effect of aLT on reduction of NSS/QOLD score was higher than that of aH.
  • Effect of combination drug treatment was able to be evaluated in aH + topical steroids (tS) in 95 cases, aLT + tS in 12 cases and aH + aLT in 25 cases.
  • CONCLUSION: JRQLQ is useful questionnaire for general clinic to evaluate the QOL disturbances induced by JCP and to follow clinical process relating to QOL changes including effect of drug treatment.
  • [MeSH-major] Anti-Allergic Agents / therapeutic use. Cryptomeria. Pollen / immunology. Quality of Life. Rhinitis, Allergic, Seasonal / drug therapy. Rhinitis, Allergic, Seasonal / epidemiology

  • MedlinePlus Health Information. consumer health - Hay Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15719651.001).
  • [ISSN] 0021-4884
  • [Journal-full-title] Arerugī = [Allergy]
  • [ISO-abbreviation] Arerugi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Allergic Agents
  •  go-up   go-down


39. García-Mediavilla V, Villares C, Culebras JM, Báyon JE, González-Gallego J: Effects of dietary beta-cyclodextrin in hypercholesterolaemic rats. Pharmacol Toxicol; 2003 Feb;92(2):94-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Beta-cyclodextrin is a compound that forms inclusion complexes with a variety of molecules, specially bile acids and sterols.
  • [MeSH-major] Anticholesteremic Agents / pharmacology. Cholesterol, Dietary / administration & dosage. Cyclodextrins / pharmacology. Diet. Hypercholesterolemia / drug therapy. beta-Cyclodextrins
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Bile / metabolism. Bile Acids and Salts / metabolism. Cholesterol / metabolism. Cholesterol 7-alpha-Hydroxylase / metabolism. Eating / drug effects. Feces / chemistry. Liver / chemistry. Liver / drug effects. Liver / metabolism. Liver / pathology. Male. Rats. Rats, Wistar. Weight Gain / drug effects

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12747579.001).
  • [ISSN] 0901-9928
  • [Journal-full-title] Pharmacology & toxicology
  • [ISO-abbreviation] Pharmacol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Bile Acids and Salts; 0 / Cholesterol, Dietary; 0 / Cyclodextrins; 0 / beta-Cyclodextrins; 97C5T2UQ7J / Cholesterol; EC 1.14.13.17 / Cholesterol 7-alpha-Hydroxylase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; JV039JZZ3A / betadex
  •  go-up   go-down


40. Chen CF, Hsueh CW, Tang TS, Wang D, Shen CY, Pei JS: Reperfusion liver injury-induced superoxide dismutase and catalase expressions and the protective effects of N-acetyl cysteine. Transplant Proc; 2007 May;39(4):858-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reperfusion liver injury-induced superoxide dismutase and catalase expressions and the protective effects of N-acetyl cysteine.
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Gene Expression Regulation, Enzymologic / drug effects. Male. RNA, Messenger / genetics. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524832.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; EC 2.6.1.2 / Alanine Transaminase; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


41. Ramarokoto CE, Rakotomanana F, Ratsitorahina M, Raharimanga V, Razafindratsimandresy R, Randremanana R, Rakoto-Andrianarivelo M, Rousset D, Andrianaja V, Richard V, Soares JL, Rabarijaona LP: Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar. BMC Infect Dis; 2008;8:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The overall prevalence in south and east Africa region has been estimated to be 1.6% but limited information about the epidemiology of HCV infection in Madagascar is available METHODS: A cross-sectional survey for hepatitis C antibodies was conducted in 2,169 subjects of the general population of Antananarivo to determine seroprevalence of hepatitis C and associated risk factors.
  • The variable history of hospitalization, previous therapeutic injections, dental treatment, intravenous drug use, and abnormal ALT and AST were statistically significantly related with the presence of HCV antibodies.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Epidemiol. 2001;17(1):47-51 [11523575.001]
  • [Cites] East Afr Med J. 1995 Jun;72(6):362-4 [7498004.001]
  • [Cites] Lancet Infect Dis. 2002 May;2(5):293-302 [12062995.001]
  • [Cites] Acta Gastroenterol Belg. 2002 Apr-Jun;65(2):78-9 [12148442.001]
  • [Cites] Arch Inst Pasteur Madagascar. 1996;63(1-2):62-6 [12463021.001]
  • [Cites] J Med Virol. 2003 Mar;69(3):384-90 [12526049.001]
  • [Cites] Gastroenterol Clin Biol. 2000 Feb;24(2):169-73 [12687957.001]
  • [Cites] Rev Gastroenterol Mex. 2002 Oct;67 Suppl 2:S7-8 [12712842.001]
  • [Cites] Bull World Health Organ. 2003;81(7):491-500 [12973641.001]
  • [Cites] Intervirology. 2004;47(1):32-40 [15044834.001]
  • [Cites] APMIS. 1992 Sep;100(9):851-5 [1382461.001]
  • [Cites] Hepatology. 1993 Feb;17(2):183-7 [8381381.001]
  • [Cites] Am J Trop Med Hyg. 1993 Oct;49(4):435-9 [7692753.001]
  • [Cites] Med Trop (Mars). 1996;56(4):393-9 [9139200.001]
  • [Cites] Hepatology. 1997 Jun;25(6):1490-6 [9185773.001]
  • [Cites] Bull Soc Pathol Exot. 1997;90(1):3-5 [9264746.001]
  • [Cites] Gastroenterology. 1999 Apr;116(4):893-9 [10092311.001]
  • [Cites] Commun Dis Intell Q Rep. 2004;28(4):517-21 [15745402.001]
  • [Cites] Int J Epidemiol. 2005 Jun;34(3):593-9 [15802378.001]
  • [Cites] J Med Virol. 2006 Sep;78(9):1185-9 [16847958.001]
  • [Cites] J Med Virol. 2007 Aug;79(8):1082-8 [17596831.001]
  • [Cites] J Med Virol. 2007 Sep;79(9):1322-4 [17607776.001]
  • [Cites] Bull World Health Organ. 1999;77(10):789-800 [10593026.001]
  • [Cites] J Viral Hepat. 1999 Jan;6(1):35-47 [10847128.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jun;12(6):667-78 [10912488.001]
  • [Cites] Am J Trop Med Hyg. 2000 Nov-Dec;63(5-6):236-41 [11421370.001]
  • [Cites] Am J Trop Med Hyg. 2001 Mar-Apr;64(3-4):147-53 [11442209.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1993 Oct;14(5):271-4 [7511060.001]
  • [Cites] J Hepatol. 1994 Oct;21(4):634-40 [7529274.001]
  • [Cites] Bull Soc Pathol Exot. 1994;87(3):138-42 [7827511.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1994 Nov-Dec;88(6):657 [7886760.001]
  • [Cites] Scand J Infect Dis. 1995;27(2):99-104 [7544914.001]
  • [Cites] J Hepatol. 2001 Oct;35(4):531-7 [11682041.001]
  • (PMID = 18312652.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis C Antibodies
  • [Other-IDs] NLM/ PMC2292193
  •  go-up   go-down


42. Benoit DS, Henry SM, Shubin AD, Hoffman AS, Stayton PS: pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol Pharm; 2010 Apr 5;7(2):442-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.
  • Here, pH-responsive complexes were developed for the delivery of siRNA in order to sensitize drug-resistant ovarian cancer cells (NCI/ADR-RES) to doxorubicin.
  • The electrostatic complexes consisted of a cationic micelle used as a nucleating core, siRNA, and a pH-responsive endosomolytic polymer.
  • The pH-responsive ternary complexes were used to deliver siRNA against polo-like kinase 1 (plk1), a gene upregulated in many cancers and responsible for cell cycle progression, to ovarian cancer cell lines.
  • Treatment resulted in approximately 50% reduction of plk1 gene expression in the drug-resistant NCI/ADR-RES ovarian cancer cell model and in the drug-sensitive parental cell line, OVCAR8.
  • To demonstrate the potential for dual delivery from this polymer system, micelle cores were subsequently loaded with doxorubicin and utilized in ternary complexes to achieve cell sensitization through simultaneous siRNA and drug delivery from a single carrier.
  • These results show knockdown of plk1 results in sensitization of multidrug resistant cells to doxorubicin, and this combination of gene silencing and small molecule drug delivery may prove useful to achieve potent therapeutic effects.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomacromolecules. 2007 Jun;8(6):1951-7 [17472337.001]
  • [Cites] Biomaterials. 2007 Oct;28(28):4132-42 [17582489.001]
  • [Cites] J Control Release. 2007 Oct 8;122(3):217-25 [17574292.001]
  • [Cites] Biomacromolecules. 2008 Feb;9(2):444-55 [18186606.001]
  • [Cites] J Biomed Opt. 2008 Jan-Feb;13(1):014025 [18315383.001]
  • [Cites] Nanomedicine (Lond). 2008 Apr;3(2):137-40 [18373419.001]
  • [Cites] Nat Biotechnol. 2008 May;26(5):561-9 [18438401.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7975-84 [18829555.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):672-6 [10980711.001]
  • [Cites] Annu Rev Biochem. 2000;69:531-69 [10966468.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):535-6 [11102900.001]
  • [Cites] Biosci Rep. 2000 Oct;20(5):419-32 [11332603.001]
  • [Cites] Gene Ther. 2001 May;8(9):713-24 [11406766.001]
  • [Cites] Lancet. 2002 Jan 12;359(9301):131-2 [11809257.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3162-71 [12082631.001]
  • [Cites] J Natl Cancer Inst. 2002 Dec 18;94(24):1863-77 [12488480.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1515-9 [12670898.001]
  • [Cites] Biochem J. 2003 May 15;372(Pt 1):65-75 [12583812.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5789-94 [12732729.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jun;4(6):457-67 [12778125.001]
  • [Cites] Curr Gene Ther. 2003 Aug;3(4):281-304 [12871018.001]
  • [Cites] Eur J Pharm Biopharm. 2003 Sep;56(2):237-46 [12957638.001]
  • [Cites] Biochem J. 2004 Jan 1;377(Pt 1):159-69 [14505488.001]
  • [Cites] Bioconjug Chem. 2004 Mar-Apr;15(2):326-32 [15025528.001]
  • [Cites] Cancer Gene Ther. 2004 May;11(5):309-16 [15031723.001]
  • [Cites] J Control Release. 2004 May 18;96(3):379-91 [15120895.001]
  • [Cites] J Pharm Pharm Sci. 2003 Sep-Dec;6(3):321-6 [14738712.001]
  • [Cites] J Biol Chem. 2004 Jun 11;279(24):25549-61 [15024021.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8676-81 [15173599.001]
  • [Cites] Mol Cell. 2004 Sep 10;15(5):799-811 [15350223.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13227-32 [15328416.001]
  • [Cites] J Control Release. 2004 Sep 30;99(2):329-37 [15380641.001]
  • [Cites] J Immunol Methods. 1983 May 27;60(1-2):115-24 [6406600.001]
  • [Cites] Oncogene. 2008 Dec 4;27(57):7212-22 [18794807.001]
  • [Cites] Mol Cancer. 2009;8:1 [19128456.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Mar;63(4):711-22 [18618115.001]
  • [Cites] J Control Release. 2009 Feb 10;133(3):221-9 [18973780.001]
  • [Cites] Exp Biol Med (Maywood). 2009 Feb;234(2):123-31 [19064945.001]
  • [Cites] Neurochem Res. 2009 May;34(5):984-90 [18937067.001]
  • [Cites] Cancer Lett. 2009 Jul 18;280(1):110-9 [19299075.001]
  • [Cites] Mol Pharmacol. 2009 Jun;75(6):1364-73 [19264847.001]
  • [Cites] Small. 2009 Aug 17;5(16):1862-8 [19384879.001]
  • [Cites] Lung Cancer. 2009 Dec;66(3):292-7 [19328586.001]
  • [Cites] J Biol Chem. 1994 Apr 29;269(17):12918-24 [8175709.001]
  • [Cites] Curr Biol. 1995 Mar 1;5(3):265-74 [7780737.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 19;234(2):397-405 [9177283.001]
  • [Cites] Jpn J Cancer Res. 1998 Feb;89(2):221-7 [9548451.001]
  • [Cites] J Control Release. 1998 Mar 31;52(3):239-52 [9743445.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2794-7 [10383133.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):748-56 [15375377.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):275-86 [15766665.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4487-94 [15958634.001]
  • [Cites] J Control Release. 2005 May 18;104(2):417-27 [15984055.001]
  • [Cites] Orthod Craniofac Res. 2005 Aug;8(3):219-25 [16022724.001]
  • [Cites] Nat Biotechnol. 2005 Aug;23(8):1002-7 [16041363.001]
  • [Cites] J Gene Med. 2005 Aug;7(8):992-1009 [15920783.001]
  • [Cites] Nucleic Acids Res. 2005;33(22):e190 [16352864.001]
  • [Cites] Biomol Eng. 2006 Mar;23(1):17-34 [16466964.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):321-30 [16557283.001]
  • [Cites] Nature. 2006 May 4;441(7089):111-4 [16565705.001]
  • [Cites] FEBS Lett. 2006 Jun 26;580(15):3624-30 [16753148.001]
  • [Cites] Biomacromolecules. 2006 Aug;7(8):2407-14 [16903689.001]
  • [Cites] Pharm Res. 2006 Aug;23(8):1868-76 [16845585.001]
  • [Cites] Adv Drug Deliv Rev. 2006 Dec 1;58(14):1523-31 [17079050.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3170-80 [17172421.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):350-2 [16504380.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):40-7 [16644108.001]
  • [Cites] Bioconjug Chem. 2007 Jan-Feb;18(1):13-8 [17226953.001]
  • [Cites] Nat Rev Genet. 2007 Mar;8(3):173-84 [17304245.001]
  • [Cites] Bioconjug Chem. 2007 May-Jun;18(3):736-45 [17358044.001]
  • [Cites] Bioconjug Chem. 2007 May-Jun;18(3):1010-4 [17402703.001]
  • [Cites] Mol Cancer Ther. 2007 May;6(5):1650-60 [17513613.001]
  • (PMID = 20073508.001).
  • [ISSN] 1543-8392
  • [Journal-full-title] Molecular pharmaceutics
  • [ISO-abbreviation] Mol. Pharm.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB002991-01; United States / NIBIB NIH HHS / EB / R01 EB002991; United States / NIBIB NIH HHS / EB / EB2991; United States / NIBIB NIH HHS / EB / R01 EB002991-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Methacrylates; 0 / Micelles; 0 / Nylons; 0 / Polymers; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / poly(2-(dimethylamino)ethyl methacrylate); 80168379AG / Doxorubicin; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1; R5QX287XXU / butyl methacrylate
  • [Other-IDs] NLM/ NIHMS221336; NLM/ PMC2920053
  •  go-up   go-down


43. Yoneda M, Endo H, Nozaki Y, Tomimoto A, Fujisawa T, Fujita K, Yoneda K, Takahashi H, Saito S, Iwasaki T, Yamamoto S, Tsutsumi S, Aburatani H, Wada K, Hotta K, Nakajima A: Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. J Pharmacol Sci; 2007 Oct;105(2):151-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the expression profiles of approximately 50,000 genes and biological pathways in NASH patients in comparison with simple steatosis patients by using the analytical technique of GSEA (Gene Set Enrichment Analysis) by DNA microarrays.
  • In conclusion, the results confirmed involvement of the PPARgamma pathway in NASH and the therapeutic utility of a PPARgamma ligand.
  • [MeSH-major] Fatty Liver / drug therapy. Gene Expression Regulation. PPAR gamma / metabolism
  • [MeSH-minor] Alanine Transaminase / blood. Alanine Transaminase / drug effects. Gene Expression Profiling. Humans. Hypoglycemic Agents / administration & dosage. Hypoglycemic Agents / pharmacology. Oligonucleotide Array Sequence Analysis. Thiazolidinediones / administration & dosage. Thiazolidinediones / pharmacology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PIOGLITAZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928738.001).
  • [ISSN] 1347-8613
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / PPAR gamma; 0 / Thiazolidinediones; EC 2.6.1.2 / Alanine Transaminase; X4OV71U42S / pioglitazone
  • [Number-of-references] 49
  •  go-up   go-down


44. Wang ZY, Zhang DZ, Shi XF, Zhou Z, Ren H: [Investigation of entecavir medication of chronic hepatitis B patients in the Chongqing area who failed lamivudine treatment]. Zhonghua Gan Zang Bing Za Zhi; 2007 Jan;15(1):13-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation of entecavir medication of chronic hepatitis B patients in the Chongqing area who failed lamivudine treatment].
  • METHODS: This was part of a multicenter, double-blinded, randomized (4:1) and placebo-controlled trial comparing the safety and efficacy of ETV (1.0 mg once q.d.) for 12 weeks in lamivudine refractory CHB patients.
  • [MeSH-major] Antiviral Agents / therapeutic use. Guanine / analogs & derivatives. Hepatitis B, Chronic / drug therapy
  • [MeSH-minor] Adult. DNA, Viral / blood. Double-Blind Method. Female. Hepatitis B virus / drug effects. Hepatitis B virus / physiology. Humans. Lamivudine / therapeutic use. Treatment Failure. Virus Replication / drug effects. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17244451.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 2T8Q726O95 / Lamivudine; 5968Y6H45M / entecavir; 5Z93L87A1R / Guanine
  •  go-up   go-down


45. Zhu XX, Avandia Phase IV Study Group: [The safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus in China]. Zhonghua Nei Ke Za Zhi; 2003 Sep;42(9):636-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus in China].
  • OBJECTIVE: To assess the clinical safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus.
  • All serious adverse events (SAE) were considered by the investigator being not related to study medication except one case of SAE which was considered to be possibly related to the study medication.
  • CONCLUSIONS: In this 12-week phase IV study, rosiglitazone maleate was found to be safe and well tolerated in all the three cohorts receiving rosiglitazone maleate as monotherapy or in combination with SU or MET for a large sample of population of patients with type 2 diabetes.
  • [MeSH-major] Diabetes Mellitus, Type 2 / drug therapy. Hypoglycemic Agents / therapeutic use. Thiazolidinediones / therapeutic use


46. Wang Y, Chang F, Zhang Y, Liu N, Liu G, Gupta S, Rusckowski M, Hnatowich DJ: Pretargeting with amplification using polymeric peptide nucleic acid. Bioconjug Chem; 2001 Sep-Oct;12(5):807-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretargeting with amplification using polymeric peptide nucleic acid.
  • One goal of this investigation was to develop a polymer conjugated with multiple copies of peptide nucleic acid (PNA) and with pharmacokinetic properties suitable for applications in vivo.
  • Using (99m)Tc-MAG(3)-cPNA, targeting of PNA-PA-PEG was studied in vitro and in vivo in inflammation and tumor mouse models, in both cases relying upon nonspecific diffusion for localization.
  • In addition, cPNA-avidin was considered as a clearing agent with biotinylated PNA-PA-PEG.
  • In both the inflammation and tumor mouse models, between 35 and 60% of these PNAs could be targeted in the lesions.
  • [MeSH-major] Nucleic Acid Amplification Techniques / methods. Peptide Nucleic Acids / pharmacokinetics. Polymers / pharmacokinetics. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Animals. Disease Models, Animal. Drug Delivery Systems. Drug Evaluation, Preclinical. Drug Stability. Inflammation / radionuclide imaging. Male. Mice. Mice, Inbred Strains. Neoplasms, Experimental / radionuclide imaging. Nucleic Acid Hybridization. Polyethylene Glycols / chemistry. Polyethylene Glycols / pharmacokinetics. Technetium. Tissue Distribution

  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11562199.001).
  • [ISSN] 1043-1802
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA79507
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Nucleic Acids; 0 / Polymers; 0 / Radiopharmaceuticals; 30IQX730WE / Polyethylene Glycols; 7440-26-8 / Technetium
  •  go-up   go-down


47. Akman SA, Okcu SC, Halicioğlu O, Sutcuoglu S, Anil M, Kizilgunesler A, Bakiler AR: Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B. Pediatr Int; 2007 Dec;49(6):848-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Interferon (IFN)-alpha and lamivudine (LAM), a nucleoside analog, are frequently used drugs for the treatment of chronic hepatitis B (CHB), and their combined therapy has been shown to be effective.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis B, Chronic / drug therapy. Interferon-alpha / therapeutic use. Lamivudine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. DNA, Viral / blood. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Humans. Male. Treatment Outcome. Viral Load

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18045284.001).
  • [ISSN] 1328-8067
  • [Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society
  • [ISO-abbreviation] Pediatr Int
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Interferon-alpha; 2T8Q726O95 / Lamivudine
  •  go-up   go-down


48. Kubota S, Amino N, Matsumoto Y, Ikeda N, Morita S, Kudo T, Ohye H, Nishihara E, Ito M, Fukata S, Miyauchi A: Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis. Thyroid; 2008 Mar;18(3):283-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: When the liver function tests are aggravated after starting antithyroid drugs (ATDs) in Graves' hyperthyroidism, discontinuation of ATDs is generally considered.
  • However, a question arises whether such aggravation constitutes an adverse effect of the drugs or not.
  • MAIN OUTCOMES: Twenty-three (76.7%) untreated Graves' disease patients and 14 (51.9%) untreated painless thyroiditis patients were found to have at least one liver function test abnormality.
  • [MeSH-major] Antithyroid Agents / adverse effects. Graves Disease / drug therapy. Liver Diseases / etiology. Liver Function Tests. Thyroiditis / drug therapy. Thyrotoxicosis / drug therapy
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Alkaline Phosphatase / blood. Aspartate Aminotransferases / blood. Disease Progression. Drug Monitoring. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pain. Prospective Studies. gamma-Glutamyltransferase / blood

  • Genetic Alliance. consumer health - Graves' Disease.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18001177.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antithyroid Agents; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


49. Ayaz C, Celen MK, Colak H, Hosoglu S, Geyik MF: Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B. Indian J Gastroenterol; 2006 Mar-Apr;25(2):71-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To compare the efficacy of a combination of a-interferon (IFN-a) and lamivudine with IFN-a alone in the treatment of patients with HBeAg-positive chronic hepatitis B (CHB).
  • In Group 1 (n=31), mean (SD) ALT levels decreased from 124 (59) IU/L to 39 (18) IU/L at 12 months; corresponding values in Group 2 (n=33) were 128 (57) and 56 (11) IU/L (p< 0.05).
  • [MeSH-major] Antiviral Agents / administration & dosage. Hepatitis B e Antigens / blood. Hepatitis B, Chronic / drug therapy. Interferon-alpha / administration & dosage. Lamivudine / administration & dosage
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Humans. Male. Recombinant Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763334.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis B e Antigens; 0 / Interferon-alpha; 0 / Recombinant Proteins; 2T8Q726O95 / Lamivudine; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


50. Kryshtal' MV: [Effect of chronic acidosis on protein metabolism]. Fiziol Zh; 2003;49(5):58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In experiments on mongrel albino male rats, we studied the effects of 30 mmol/kg lactic acid, 30 mmol/kg NaHCO3, and 20 mmol/kg NH4Cl (intraventricular injections, daily for 7 days) on the contents of total protein, residual nitrogen, urea, and creatinine in the blood, as well as on the activities of aldolase and alanine aminotranspherase (ALT).
  • We also studied the effects of the above agents on renal functions: glomerular filtration rate (GFR), diuresis, and excretion of ammonium, creatinine, and protein with urine.
  • In contrast, under conditions of chronic alkalosis we observed a drop in the level of urea in the blood with no changes in the concentrations of protein and residual nitrogen, as well as a dramatic depression of the urinary NH4+ excretion.
  • These results give evidence for spending a great number of amino acids on the renal ammoniogenesis at chronical acidosis; their saving at alkalosis; an impairment of the protein synthesis, and an increase in protein catabolism at acidosis to replenish the pool of amino acids, as well as for an activation of the urea synthesis to eliminate the excessive amount of NH4+ from the blood.
  • [MeSH-major] Acidosis / metabolism. Blood Proteins / metabolism
  • [MeSH-minor] Alkalosis / chemically induced. Alkalosis / metabolism. Alkalosis / physiopathology. Ammonium Chloride / toxicity. Animals. Blood Urea Nitrogen. Carbonates / toxicity. Creatinine / blood. Diuresis / drug effects. Diuresis / physiology. Glomerular Filtration Rate / drug effects. Glomerular Filtration Rate / physiology. Lactic Acid / toxicity. Male. Rats. Urinalysis

  • Hazardous Substances Data Bank. AMMONIUM CHLORIDE .
  • Hazardous Substances Data Bank. SODIUM CARBONATE .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14663891.001).
  • [Journal-full-title] Fiziolohichnyĭ zhurnal (Kiev, Ukraine : 1994)
  • [ISO-abbreviation] Fiziol Zh
  • [Language] ukr
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Carbonates; 01Q9PC255D / Ammonium Chloride; 33X04XA5AT / Lactic Acid; 45P3261C7T / sodium carbonate; AYI8EX34EU / Creatinine
  •  go-up   go-down


51. Gutierrez RM, Navarro YT: Antioxidant and hepatoprotective effects of the methanol extract of the leaves of Satureja macrostema. Pharmacogn Mag; 2010 Apr;6(22):125-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Satureja Macrostema is used both as a functional food and as a drug.
  • The extract exhibited powerful free radical scavenging, especially against DPPH, hydroxyl radical scavenging and iron-chelating activity as well as a moderate effect on NO and superoxide anions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Chem Toxicol. 1978;1(2):163-71 [755666.001]
  • [Cites] Fitoterapia. 2006 Feb;77(2):91-3 [16376022.001]
  • [Cites] Int J Tissue React. 1991;13(2):79-85 [1659560.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(4):1620-4 [2154753.001]
  • [Cites] Indian J Med Res. 1990 Aug;92:276-83 [2228074.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):2-9 [2403415.001]
  • [Cites] J Pharm Pharmacol. 1987 Dec;39(12):1047-9 [2894438.001]
  • [Cites] J Lipid Res. 1970 Nov;11(6):583-95 [4100998.001]
  • [Cites] Biochem Biophys Res Commun. 1972 Jan 31;46(2):849-54 [4400444.001]
  • [Cites] Clin Chem. 1973 Jan;19(1):92-8 [4683373.001]
  • [Cites] J Pharmacol Exp Ther. 1973 Oct;187(1):185-94 [4746326.001]
  • [Cites] Clin Chem. 1974 Apr;20(4):470-5 [4818200.001]
  • [Cites] Clin Chem. 1972 Feb;18(2):97-104 [5008530.001]
  • [Cites] Anal Biochem. 1982 Oct;126(1):131-8 [7181105.001]
  • [Cites] J Ethnopharmacol. 2000 Sep;72(1-2):35-42 [10967451.001]
  • [Cites] J Ethnopharmacol. 2001 May;75(2-3):169-74 [11297846.001]
  • [Cites] J Agric Food Chem. 2001 Nov;49(11):5165-70 [11714298.001]
  • [Cites] J Agric Food Chem. 2002 Mar 13;50(6):1619-24 [11879046.001]
  • [Cites] Am J Clin Pathol. 1957 Jul;28(1):56-63 [13458125.001]
  • [Cites] Arch Biochem Biophys. 1959 May;82(1):70-7 [13650640.001]
  • [Cites] J Appl Toxicol. 1992 Dec;12(6):439-42 [1360480.001]
  • (PMID = 20668579.001).
  • [ISSN] 0976-4062
  • [Journal-full-title] Pharmacognosy magazine
  • [ISO-abbreviation] Pharmacogn Mag
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2900060
  • [Keywords] NOTNLM ; Satureja Macrostema / antioxidant effect / biochemical parameters / hepatoprotective activity
  •  go-up   go-down


52. Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y: A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug 15;31(6):1255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study.
  • OBJECTIVE: Atypical antipsychotic drugs commonly cause asymptomatic increase in the liver enzymes and serum bilirubin levels.
  • In this article we aimed to evaluate the effect of atypical antipsychotic drugs namely olanzapine, risperidone and quetiapine on the hepatic enzymes and serum bilirubin levels in psychiatric patients.
  • CONCLUSION: These results were in accordance with previous studies that asymptomatic increase of liver enzymes are common but significant liver enzyme elevations are rare during atypical antipsychotic treatment.
  • We suggest that obtaining baseline liver enzyme tests before atypical antipsychotic therapy and monitoring regularly specifically in patients with risk factors for liver damage during therapy.
  • [MeSH-major] Antipsychotic Agents / pharmacology. Liver / drug effects. Mental Disorders / pathology

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600607.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.1 / Alkaline Phosphatase; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


53. Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, Malekzadeh R: Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci; 2008 Aug;53(8):2246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Probucol, a lipid-lowering agent with antioxidant effects, is effective in normalizing liver enzymes in patients with nonalcoholic steatohepatitis (NASH).
  • No adverse drug effects were observed.
  • [MeSH-major] Anticholesteremic Agents / therapeutic use. Antioxidants / therapeutic use. Fatty Liver / drug therapy. Liver / drug effects. Probucol / therapeutic use

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2467-74 [10484010.001]
  • [Cites] J Hepatol. 2003 Apr;38(4):414-8 [12663231.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004996 [17253535.001]
  • [Cites] J Hepatol. 2005;42 Suppl(1):S2-12 [15777569.001]
  • [Cites] J Hepatol. 2005 Jan;42(1):132-8 [15629518.001]
  • [Cites] World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253 [11234459.001]
  • [Cites] Hepatology. 2004 Jan;39(1):188-96 [14752837.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2297-307 [17135584.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-15 [15625656.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005165 [17253543.001]
  • [Cites] Gut. 2007 Mar;56(3):443-4 [17339254.001]
  • [Cites] Endocr Pract. 2005 Sep-Oct;11(5):319-24 [16191492.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2485-90 [14638353.001]
  • [Cites] J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S44-50 [16540767.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):113-21 [16012941.001]
  • [Cites] Hepatology. 2003 Oct;38(4):1008-17 [14512888.001]
  • [Cites] J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S17-29 [16540762.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):266-8 [12590240.001]
  • [Cites] Acta Pharmacol Sin. 2000 Jul;21(7):637-40 [11360673.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Dec;4(12):1537-43 [17162245.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005166 [17253544.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1072-81 [15842581.001]
  • [Cites] J Hepatol. 2006 Jan;44(1):197-208 [16274837.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005160 [17253541.001]
  • (PMID = 18049900.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Antioxidants; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; P3CTH044XJ / Probucol
  •  go-up   go-down


54. Jaeschke H, Cover C, Bajt ML: Role of caspases in acetaminophen-induced liver injury. Life Sci; 2006 Mar 6;78(15):1670-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results emphasize that even very low doses of DMSO, which are generally necessary to dissolve water-insoluble inhibitors, can have a profound impact on the toxicity of drugs and chemicals when metabolic activation is a critical aspect of the mechanism of cell injury.
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Animals. Caspase Inhibitors. Cysteine Proteinase Inhibitors / pharmacology. Dimethyl Sulfoxide / pharmacology. Dose-Response Relationship, Drug. Drug-Induced Liver Injury. Male. Mice. Mice, Inbred Strains. Solvents / pharmacology

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226279.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA-12916; United States / NIDDK NIH HHS / DK / R01 DK-070195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Analgesics, Non-Narcotic; 0 / Caspase Inhibitors; 0 / Cysteine Proteinase Inhibitors; 0 / Solvents; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 362O9ITL9D / Acetaminophen; EC 3.4.22.- / Caspases; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


55. Tang S, Cheng IK, Leung VK, Kuok UI, Tang AW, Wing Ho Y, Neng Lai K, Mao Chan T: Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol; 2003 Nov;39(5):875-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We treated four consenting RT recipients who developed acute de novo HCV infection with a combination of interferon-alpha 2b and ribavirin.
  • Our experience indicates that the judicious use of combined interferon and ribavirin can be considered in selected RT recipients with severe acute hepatitis C infection.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C / drug therapy. Hepatitis C / etiology. Interferon-alpha / therapeutic use. Kidney Transplantation / adverse effects. Ribavirin / therapeutic use
  • [MeSH-minor] Adult. Alanine Transaminase / metabolism. Dose-Response Relationship, Drug. Drug Therapy, Combination. Genotype. Hemolysis. Hepacivirus / genetics. Humans. Liver / enzymology. Male. Middle Aged. Recombinant Proteins. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14568274.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 49717AWG6K / Ribavirin; 99210-65-8 / interferon alfa-2b; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


56. Hussain S, Khan MZ, Khan A, Javed I, Asi MR: Toxico-pathological effects in rats induced by concurrent exposure to aflatoxin and cypermethrin. Toxicon; 2009 Jan;53(1):33-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum ALT and creatinine concentrations increased while those of total proteins, albumin, serum cholesterol and triglycerides decreased.
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Body Weight / drug effects. Dose-Response Relationship, Drug. Drug-Induced Liver Injury. Insecticides / administration & dosage. Insecticides / toxicity. Liver / pathology. Liver Diseases / pathology. Rats

  • Hazardous Substances Data Bank. CYPERMETHRIN .
  • Hazardous Substances Data Bank. ALPHACYPERMETHRIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18977377.001).
  • [ISSN] 0041-0101
  • [Journal-full-title] Toxicon : official journal of the International Society on Toxinology
  • [ISO-abbreviation] Toxicon
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aflatoxins; 0 / Insecticides; 0 / Pyrethrins; 1TR49121NP / cypermethrin
  •  go-up   go-down


57. Kuloğlu Z, Kansu A, Erden E, Girgin N: Efficacy of combined interferon alpha and long-term lamivudine therapy in children with chronic hepatitis B. Turk J Pediatr; 2010 Sep-Oct;52(5):457-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In conclusion, although lamivudine was used for a longer period, the response rate was not higher than in previous reports.
  • [MeSH-major] Antiviral Agents / administration & dosage. Hepatitis B, Chronic / drug therapy. Interferon-alpha / administration & dosage. Lamivudine / administration & dosage
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Resistance / drug effects. Drug Therapy, Combination. Female. Humans. Male. Turkey

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21434529.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 2T8Q726O95 / Lamivudine
  •  go-up   go-down


58. Liu ZW, Zhang N, Han QY, Zeng JT, Chu YL, Qiu JM, Wang YW, Ma LT, Wang XQ: Correlation of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function in Chinese patients with chronic hepatitis C virus infection. World J Gastroenterol; 2005 Jun 14;11(22):3357-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function in Chinese patients with chronic hepatitis C virus infection.
  • AIM: To determine serum leptin levels and investigate their correlations with anthropometric and metabolic parameters and biochemical liver function in patients with chronic hepatitis C virus (HCV) infection and their potential clinical implications.
  • METHODS: Forty-two chronic HCV-infected patients without anti-viral treatment were enrolled in this study, 30 patients had chronic hepatitis C, 10 had cirrhosis, and 2 had hepatocellular carcinoma (HCC).
  • Thirty age- and sex-matched healthy individuals served as controls.
  • Serum leptin levels were determined by ELISA.
  • The biochemical liver function and serum lipids were determined at the same time.
  • The height and body weight of patients and controls were measured, and body mass index (BMI) and body fat were calculated simultaneously.
  • The correlations of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function were assessed statistically.
  • RESULTS: The mean of serum leptin levels in patients with chronic hepatitis C, HCV-associated cirrhosis, HCV-associated HCC and control groups was (6.13+/-3.94), (5.25+/-4.21), (4.17+/-0.28), and (3.59+/-3.44) ng/mL, respectively.
  • The serum leptin level in patients with chronic hepatitis C was significantly higher than that in controls.
  • The serum leptin levels between cirrhotic patients and controls and between male and female cirrhotic patients had no significant difference.
  • Serum leptin levels were positively-correlated with body fat, BMI, and apolipoprotein B (Apo B) in patients with chronic HCV infection.
  • The serum alanine aminotransferase (ALT) levels were closely-correlated with BMI in patients with chronic hepatitis C.
  • CONCLUSION: HCV infection interferes with fat and lipid metabolism in patients with chronic HCV infection and leptin may play a role in hepatosteatosis.
  • [MeSH-major] Hepatitis C, Chronic / metabolism. Hepatitis C, Chronic / physiopathology. Leptin / blood. Liver / metabolism. Liver / virology
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Body Mass Index. Energy Metabolism. Fatty Liver / metabolism. Fatty Liver / virology. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948239.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin
  • [Other-IDs] NLM/ PMC4315988
  •  go-up   go-down


59. Fujiyama S, Shibata J, Maeda S, Tanaka M, Noumaru S, Sato K, Tomita K: Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Br J Cancer; 2003 Nov 3;89(9):1614-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol.
  • We have performed a phase I clinical trial of an SM-11355-lipiodol formulation in 11 HCC patients, in order to investigate the maximum allowable dose and to maximize the efficacy and safety of the drug in the treatment of HCC.
  • An antitumour efficacy rating of complete response was achieved for one patient and a partial response rating was achieved for a second patient, giving an overall response rate of 18.2%.
  • Anorexia, nausea and vomiting, pyrexia, thrombocytopenia and increases in AST, ALT and total bilirubin were observed as adverse effects, but each was transient and each patient had recovered completely by 4 weeks after drug administration.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Contrast Media. Dose-Response Relationship, Drug. Humans. Infusions, Intra-Arterial. Iodized Oil / therapeutic use. Middle Aged. Platinum / blood

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Pharm Bull. 2000 Mar;23(3):344-8 [10726891.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1586-94 [2477131.001]
  • [Cites] Oncology. 2000 May;58(4):293-9 [10838494.001]
  • [Cites] Xenobiotica. 2002 May;32(5):399-409 [12065062.001]
  • [Cites] Radiology. 2002 Jul;224(1):47-54 [12091661.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Aug;19(8):1053-65 [6311559.001]
  • [Cites] Cancer. 1983 Dec 15;52(12):2193-200 [6196102.001]
  • [Cites] J Surg Oncol. 1984 Mar;25(3):218-26 [6199624.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2367-74 [6093980.001]
  • [Cites] Radiology. 1985 Jan;154(1):25-9 [2981114.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1985 Oct 25;45(10):1313-21 [3003669.001]
  • [Cites] Acta Radiol Diagn (Stockh). 1986 Mar-Apr;27(2):139-47 [2424274.001]
  • [Cites] Jpn J Cancer Res. 1986 Jun;77(6):523-5 [3015851.001]
  • [Cites] Jpn J Cancer Res. 2000 Jan;91(1):99-104 [10744050.001]
  • (PMID = 14583758.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Organoplatinum Compounds; 49DFR088MY / Platinum; 780F0P8N4I / miriplatin; 8001-40-9 / Iodized Oil
  • [Other-IDs] NLM/ PMC2394416
  •  go-up   go-down


60. Erhardt A, Behlen-Wilm U, Adams O, Donner A, Heintges T, Häussinger D: Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs. Dig Dis Sci; 2003 May;48(5):921-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Alanine Transaminase / classification. Hepatitis C, Chronic / diagnosis. Hepatitis C, Chronic / drug therapy. Interferon-alpha / administration & dosage. Ribavirin / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Injections, Subcutaneous. Liver Function Tests. Male. Pilot Projects. Prospective Studies. Recombinant Proteins. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1998 Mar;27(3):868-72 [9500720.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1485-92 [9819446.001]
  • [Cites] Hepatology. 1998 Mar;27(3):853-6 [9500717.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):760-4 [10734027.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] Gastroenterol Clin Biol. 1998 Aug-Sep;22(8-9):748-9 [9823572.001]
  • [Cites] Am J Med. 2000 Jul;109(1):62-4 [10936480.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):133S-136S [9305678.001]
  • [Cites] Hepatology. 1997 Oct;26(4):1012-7 [9328328.001]
  • [Cites] J Viral Hepat. 2001 May;8(3):202-5 [11380798.001]
  • [Cites] Dig Dis Sci. 2000 Oct;45(10):1953-8 [11117566.001]
  • [Cites] J Infect Dis. 2000 Dec;182(6):1595-601 [11069229.001]
  • [Cites] Scand J Gastroenterol. 1997 Dec;32(12):1256-60 [9438325.001]
  • [Cites] J Hepatol. 1999;31 Suppl 1:193-6 [10622586.001]
  • [Cites] J Gastroenterol Hepatol. 1997 Jan;12 (1):58-61 [9076625.001]
  • [Cites] Hepatology. 1994 May;19(5):1321-4 [8175159.001]
  • [Cites] J Pathol Bacteriol. 1962 Jul;84:53-64 [14498313.001]
  • [Cites] Clin Liver Dis. 1999 Nov;3(4):843-53 [11291254.001]
  • [Cites] J Hepatol. 1995 Nov;23 (5):503-8 [8583136.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1094-9 [10370673.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):291-5 [8536870.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):2S-10S [9305656.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92 (10 ):1793-5 [9382038.001]
  • [Cites] Hepatology. 1998 May;27(5):1443-4 [9581705.001]
  • [Cites] Z Gastroenterol. 1997 Dec;35(12):1059-67 [9487638.001]
  • [Cites] J Hepatol. 1999 May;30(5):956-61 [10365827.001]
  • [Cites] Hepatogastroenterology. 1998 Mar-Apr;45(20):321-4 [9638399.001]
  • [Cites] Scand J Gastroenterol. 2000 Apr;35(4):433-7 [10831269.001]
  • (PMID = 12772791.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b; 49717AWG6K / Ribavirin; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


61. Temple AR, Lynch JM, Vena J, Auiler JF, Gelotte CK: Aminotransferase activities in healthy subjects receiving three-day dosing of 4, 6, or 8 grams per day of acetaminophen. Clin Toxicol (Phila); 2007;45(1):36-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All doses were generally well tolerated.
  • [MeSH-minor] Adolescent. Adult. Dose-Response Relationship, Drug. Double-Blind Method. Female. Humans. Male. Middle Aged. Reference Values

  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357380.001).
  • [ISSN] 1556-3650
  • [Journal-full-title] Clinical toxicology (Philadelphia, Pa.)
  • [ISO-abbreviation] Clin Toxicol (Phila)
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 362O9ITL9D / Acetaminophen; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


62. Sposato B, Mariotta S, Ricci A, Lucantoni G, Schmid G: [Legionnaire's pneumonia with rhabdomyolysis and acute renal failure. A case report]. Recenti Prog Med; 2003 Sep;94(9):391-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Legionella pneumophyla is the agent responsible of Legionnaire's disease.

  • Genetic Alliance. consumer health - Rhabdomyolysis.
  • MedlinePlus Health Information. consumer health - Legionnaires' Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12942801.001).
  • [ISSN] 0034-1193
  • [Journal-full-title] Recenti progressi in medicina
  • [ISO-abbreviation] Recenti Prog Med
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Jasonek J, Kacprzak-Bergman I, Zaleska I: [The treatment of HCV infection with interferon alpha and ribavirin in a child with diabetes I type]. Przegl Epidemiol; 2006;60(2):259-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The treatment of HCV infection with interferon alpha and ribavirin in a child with diabetes I type].
  • [MeSH-major] Antiviral Agents / administration & dosage. Diabetes Mellitus, Type 1 / drug therapy. Hepatitis C, Chronic / drug therapy. Interferon-alpha / administration & dosage. Ribavirin / administration & dosage
  • [MeSH-minor] Adolescent. Dose-Response Relationship, Drug. Drug Combinations. Drug Therapy, Combination. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16964677.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Drug Combinations; 0 / Interferon-alpha; 0 / Rebetron; 49717AWG6K / Ribavirin
  •  go-up   go-down


64. Tang J, Zhu Y, Liu Z, Wu W, Liu Z, Shi H, Meng Q, Li M, Wu Y, Xu L: [Clinical Observation of Erlotinib in the Treatment of Advanced and Previously Treated Non-small Cell Lung Cancer.]. Zhongguo Fei Ai Za Zhi; 2009 Dec 20;12(12):1276-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this trial is to evaluate the response and adverse reaction of agent erlotinib in advanced and previously treated non-small-cell lung cancer.
  • Erlotinib was prescribed at a dose of 150 mg daily.
  • Among these patients, CR 0 case, PR 19 cases (44.2%), RR (CR+PR) 44.2% and SD 13 cases as their best response, disease control rate (DCR=CR+PR+SD) 74.4%, PD 11cases (25.6%).
  • The drug-related adverse reactions were skin rash (41 cases, 91.1%), billirubine increased (15 cases, 33.3%), ALT increased (9 cases, 20%) and diarrhea (4 cases, 8.9%).
  • It is well tolerated, only with some minimal adverse reactions.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723383.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


65. Malina L, Mottl V, Michalíková H: [Is tamoxifene porphyrinogenic?]. Cas Lek Cesk; 2005;144(4):262-4; discussion 265
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated their clinical and laboratory results and compared them with the results of the group of patients suffering also from breast tumor, but treated after the surgery with other systemic therapies, mostly with chemotherapy.
  • Diagnosis of the breast tumor was histologically confirmed in all of them.
  • We did not confirm in our patients suffering from breast tumor the results of other autors, suggesting the connection between tamoxifene-therapy and development of porphyria cutanea tarda.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Drug Eruptions / etiology. Porphyria Cutanea Tarda / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / urine. Female. Humans. Middle Aged. Porphyrins / urine

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15945486.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Porphyrins; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


66. Gao Y, Song LX, Jiang MN, Ge GY, Jia YJ: Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation; 2008 Apr;31(2):121-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis.
  • AIMS: The aim of this research is to study the effects of traditional Chinese medicine on endotoxin and its receptors in rats with nonalcoholic steatohepatitis (NASH).
  • All the animals were fed high fatty diet for 12 weeks.
  • Rats with non-alcoholic steatohepatitis (NASH) were treated with traditional Chinese medicine according to low-dose, middle-dose, high-dose and Lipitor from fifth week.
  • The levels of serum lipoid, alanine aminotransferase (ALT), endotoxin (ET), tumor necrosis factor-alpha (TNF-alpha) and interleukine-1beta (IL-1beta) were determined.
  • The expressions of lipopolysaccharide binding protein (LBP), toll-like receptor-4 (TLR-4), myeloid differentiation-2 (MD-2) and induced nitric oxide synthase (iNOS) mRNA were detected by the reverse transcription polymerase chain reaction (RT-PCR).
  • CONCLUSIONS: The mechanism of non-alcoholic steatohepatitis (NASH) maybe related to increasing the levels of serum endotoxin, upregulating endotoxin receptors of hepatic tissue and enhancing liver inflammatory injury.
  • Traditional Chinese medicine is a good treatment for non-alcoholic steatohepatitis (NASH).
  • [MeSH-major] Drugs, Chinese Herbal / pharmacology. Endotoxins / blood. Fatty Liver / drug therapy. Hepatitis / drug therapy. Liver / drug effects. Receptors, Immunologic / drug effects
  • [MeSH-minor] Acute-Phase Proteins / genetics. Acute-Phase Proteins / metabolism. Alanine Transaminase / blood. Animals. Antigens, CD14 / metabolism. Atorvastatin Calcium. Carrier Proteins / genetics. Carrier Proteins / metabolism. Dietary Fats / adverse effects. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Therapy, Combination. Heptanoic Acids / pharmacology. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Immunohistochemistry. Interleukin-1beta / blood. Lipids / blood. Lymphocyte Antigen 96 / genetics. Lymphocyte Antigen 96 / metabolism. Male. Membrane Glycoproteins / genetics. Membrane Glycoproteins / metabolism. NF-kappa B / metabolism. Nitric Oxide Synthase Type II / genetics. Nitric Oxide Synthase Type II / metabolism. Polymerase Chain Reaction. Pyrroles / pharmacology. RNA, Messenger / metabolism. Rats. Rats, Sprague-Dawley. Toll-Like Receptor 4 / genetics. Toll-Like Receptor 4 / metabolism. Tumor Necrosis Factor-alpha / blood

  • MedlinePlus Health Information. consumer health - Hepatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Biochem. 2005 Mar;38(3):203-17 [15708540.001]
  • [Cites] J Hepatol. 2006 Aug;45(2):280-9 [16635535.001]
  • [Cites] Hepatology. 2003 May;37(5):1043-55 [12717385.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1117-23 [10833486.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 4;346(3):739-45 [16781673.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1777-82 [10359581.001]
  • [Cites] Infect Immun. 2001 Jan;69(1):378-85 [11119527.001]
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] World J Gastroenterol. 2001 Feb;7(1):128-30 [11819748.001]
  • [Cites] N Engl J Med. 2000 Nov 16;343(20):1467-76 [11078773.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1413-9 [10348825.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jul 30;236(3):655-60 [9245708.001]
  • [Cites] Hepatology. 2004 Aug;40(2):376-85 [15368442.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2557-62 [9122234.001]
  • [Cites] Alcohol Clin Exp Res. 2005 Jun;29(6):1018-26 [15976528.001]
  • [Cites] Hepatology. 1990 Jan;11(1):74-80 [2295475.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21129-35 [11274165.001]
  • [Cites] J Endotoxin Res. 2003;9(1):60-4 [12691621.001]
  • [Cites] Diabetes. 2001 Aug;50(8):1844-50 [11473047.001]
  • [Cites] Gastroenterology. 2000 May;118(5):937-44 [10784593.001]
  • [Cites] Cell. 1996 Sep 20;86(6):973-83 [8808632.001]
  • [Cites] Gut. 2001 Feb;48(2):206-11 [11156641.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):513-9 [1985047.001]
  • [Cites] Mol Cell Endocrinol. 2007 Aug 15;274(1-2):35-42 [17601656.001]
  • [Cites] Infect Immun. 2001 Nov;69(11):6942-50 [11598069.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):588-93 [9435236.001]
  • [Cites] J Leukoc Biol. 2001 Aug;70(2):163-70 [11493607.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1183-92 [11266382.001]
  • [Cites] Science. 1990 Sep 21;249(4975):1431-3 [1698311.001]
  • [Cites] J Exp Med. 2003 Oct 6;198(7):1035-42 [14517279.001]
  • [Cites] J Biol Chem. 1995 May 5;270(18):10482-8 [7537731.001]
  • [Cites] J Biol Chem. 2003 May 2;278(18):15587-94 [12594207.001]
  • (PMID = 18302012.001).
  • [ISSN] 0360-3997
  • [Journal-full-title] Inflammation
  • [ISO-abbreviation] Inflammation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Antigens, CD14; 0 / Carrier Proteins; 0 / Dietary Fats; 0 / Drugs, Chinese Herbal; 0 / Endotoxins; 0 / Heptanoic Acids; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Interleukin-1beta; 0 / Lipids; 0 / Lymphocyte Antigen 96; 0 / Membrane Glycoproteins; 0 / NF-kappa B; 0 / Pyrroles; 0 / RNA, Messenger; 0 / Receptors, Immunologic; 0 / Tlr4 protein, rat; 0 / Toll-Like Receptor 4; 0 / Tumor Necrosis Factor-alpha; 0 / endotoxin receptor; 0 / lipopolysaccharide-binding protein; 48A5M73Z4Q / Atorvastatin Calcium; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, rat; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


67. Gueli N, del Nero A, Zia N, Carmenini E, Carmenini G: Life habits and cardiovascular risk in a group of bank employees in Rome. Panminerva Med; 2000 Jun;42(2):131-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: The authors believe that this study can be of some help in guiding future preventive medicine interventions that may be carried out on this population sample.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965775.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ITALY
  •  go-up   go-down


68. Dikensoy E, Balat O, Pence S, Akcali C, Cicek H: The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. Arch Gynecol Obstet; 2009 Mar;279(3):321-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Flutamide is an effective drug in treatment of hirsutism.
  • CONCLUSION: We conclude that flutamide in a dosage of 125 or 250 mg daily is a safe drug in the long-term treatment of hirsutism.
  • [MeSH-major] Androgen Antagonists / adverse effects. Drug-Induced Liver Injury. Flutamide / adverse effects. Hirsutism / drug therapy
  • [MeSH-minor] Adolescent. Adult. Alanine Transaminase / blood. Aspartate Aminotransferases / blood. Dose-Response Relationship, Drug. Female. Humans. Liver Diseases / blood. Liver Diseases / enzymology. Young Adult

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607612.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists; 76W6J0943E / Flutamide; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


69. Yaeesh S, Jamal Q, Shah AJ, Gilani AH: Antihepatotoxic activity of Saussurea lappa extract on D-galactosamine and lipopolysaccharide-induced hepatitis in mice. Phytother Res; 2010 Jun;24 Suppl 2:S229-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The improvement in plasma enzyme levels was further verified by histopathology of the liver, which showed improved architecture, absence of parenchyma congestion, decreased cellular swelling and apoptotic cells in treatment groups as compared to the toxin group of animals.
  • [MeSH-major] Drug-Induced Liver Injury / drug therapy. Plant Extracts / pharmacology. Saussurea / chemistry
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Female. Galactosamine / toxicity. Lipopolysaccharides / toxicity. Liver / drug effects. Liver / pathology. Male. Mice. Mice, Inbred BALB C. Plant Roots / chemistry. Protective Agents / pharmacology. Toxicity Tests, Acute

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Phytother Res. 2010 Jun;24 Suppl 2:S233-4
  • (PMID = 20041433.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lipopolysaccharides; 0 / Plant Extracts; 0 / Protective Agents; 7535-00-4 / Galactosamine; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


70. Chattopadhyay P, Verma N, Verma A, Kamboj T, Khan NA, Wahi AK: L-arginine protects from pringle manoeuvere of ischemia-reperfusion induced liver injury. Biol Pharm Bull; 2008 May;31(5):890-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Apoptosis / drug effects. Aspartate Aminotransferases / blood. Cell Death / drug effects. Constriction. Hepatic Artery / drug effects. Hepatocytes / drug effects. Hepatocytes / metabolism. Malondialdehyde / metabolism. Microscopy, Electron, Transmission. Nitric Oxide / metabolism. Rats. Rats, Wistar. Vasodilation / drug effects

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451513.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 31C4KY9ESH / Nitric Oxide; 4Y8F71G49Q / Malondialdehyde; 94ZLA3W45F / Arginine; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


71. Robak T: Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma; 2004 Feb;45(2):205-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ALT is a humanized rat IgG1 antibody that binds to the cell membrane of virtually all normal as well as malignant lymphocytes.
  • The activity of ALT and RIT in CLL patients resistant to FA and their synergistic interactions with cytotoxic drugs suggests that a combination of these agents may lead to further progress in the treatment of this disease.
  • The T-cell variant of PLL has demonstrated impressive responses to ALT in several trials even if the patients were refractory to deoxycoformycin (DCF) and other agents.
  • The presented results indicate that these agents are highly active and well tolerated even if the patients were resistant to 2-CdA or DCF.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / pharmacology. Antigens, CD / biosynthesis. Antigens, CD19 / biosynthesis. Antigens, CD20 / biosynthesis. Antigens, CD5 / biosynthesis. Antigens, Differentiation, B-Lymphocyte / biosynthesis. Antigens, Neoplasm / biosynthesis. Antineoplastic Combined Chemotherapy Protocols. Cell Membrane / metabolism. Combined Modality Therapy. Glycoproteins / biosynthesis. Humans. Lectins / biosynthesis. Leukemia, B-Cell / therapy. Leukemia, Hairy Cell / therapy. Leukemia, Myeloid / therapy. Lymphatic Metastasis. Lymphocytes / metabolism. Middle Aged. Pentostatin / pharmacology. Rats. Rituximab. Sialic Acid Binding Ig-like Lectin 2. Simplexvirus / metabolism. Stem Cell Transplantation

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15101704.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Antigens, CD5; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CD22 protein, human; 0 / CD52 antigen; 0 / Cell Adhesion Molecules; 0 / Glycoproteins; 0 / Lectins; 0 / Sialic Acid Binding Ig-like Lectin 2; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 108
  •  go-up   go-down


72. Zeng QY, Liu L, Zeng HS, Yu MH, Ye QC, Den L, Gong ST, Lai JP, Su YL, Tao JP: [Clinical characteristics and prognosis of 33 children with severe acute respiratory syndrome in Guangzhou area]. Zhonghua Er Ke Za Zhi; 2003 Jun;41(6):408-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Since the outbreak of a highly contagious new pneumonia, atypical pneumonia or severe acute respiratory syndrome (SARS) occurred in Guangzhou area, 33 children with this syndrome were treated in the authors' hospital.
  • Treatment included isolation, good ventilation of the ward, bed rest, supportive regimens, low volume oxygen inhalation, use of Chinese traditional medicine, antibiotics to prevent bacterial infection, and anti-inflammation therapy.
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / therapeutic use. Bed Rest. Child. Child, Preschool. China. Cohort Studies. Cough / complications. Female. Fever / complications. Humans. Infant. Length of Stay. Lung / drug effects. Lung / microbiology. Lung / pathology. Male. Prognosis. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14748989.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


73. El-Nekeety AA, El-Kholy W, Abbas NF, Ebaid A, Amra HA, Abdel-Wahhab MA: Efficacy of royal jelly against the oxidative stress of fumonisin in rats. Toxicon; 2007 Aug;50(2):256-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Animals received FB showed severe histological and histochemical changes in liver and kidney tissues.
  • These improvements were pronounced in animals fed FB-contaminated diet plus the high dose of RJ.
  • [MeSH-major] Fatty Acids / pharmacology. Fumonisins / antagonists & inhibitors. Fumonisins / toxicity. Oxidative Stress / drug effects
  • [MeSH-minor] Animals. Eating / drug effects. Glutathione Peroxidase / metabolism. Kidney / pathology. Lipids / blood. Liver / pathology. Liver Function Tests. Male. Malondialdehyde / metabolism. Rats. Rats, Wistar. Superoxide Dismutase / metabolism

  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490698.001).
  • [ISSN] 0041-0101
  • [Journal-full-title] Toxicon : official journal of the International Society on Toxinology
  • [ISO-abbreviation] Toxicon
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Fumonisins; 0 / Lipids; 4Y8F71G49Q / Malondialdehyde; 8031-67-2 / royal jelly; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


74. McKinnell J, Tayek JA: Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis. J Clin Rheumatol; 2009 Sep;15(6):303-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 48 year old African-American male with history of hypertension and chronic gout on colchicine 0.6 mg daily presented with symptoms of a community acquired pneumonia.
  • On hospital day five, the patient was discharged on oral anti-hypertensive medication and a ten-day course of doxycycline.
  • Metabolism of colchicine by the cytochrome P450 3A4 system has been previously described, but this is the first published report of colchicine associated rhabdomyolysis secondary to drug metabolism interactions with an antibiotic.
  • A review of medications that are metabolized via the cytochrome 3A4 and A-SLAVED-LIVER (Amiodarone, Simvastatin, Lovastatin, Atorvastatin, Verapamil, Erythromycin, Diltiazem, cLarithromycin, Itraconazole, Voriconazole, colchicinE, Ritonavir) pneumonic was established.
  • [MeSH-major] Anti-Bacterial Agents / adverse effects. Clarithromycin / adverse effects. Colchicine / adverse effects. Gout Suppressants / adverse effects. Rhabdomyolysis / chemically induced
  • [MeSH-minor] Ceftriaxone / therapeutic use. Community-Acquired Infections / drug therapy. Doxycycline / therapeutic use. Drug Interactions. Gout / drug therapy. Humans. Male. Middle Aged. Pneumonia, Bacterial / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Rhabdomyolysis.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • Hazardous Substances Data Bank. COLCHICINE .
  • Hazardous Substances Data Bank. Clarithromycin .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Rheumatol. 2014 Dec;20(8):457 [25417692.001]
  • (PMID = 19734738.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Gout Suppressants; 75J73V1629 / Ceftriaxone; H1250JIK0A / Clarithromycin; N12000U13O / Doxycycline; SML2Y3J35T / Colchicine
  •  go-up   go-down


75. Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, Stewart CF: Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol; 2004 Mar 1;22(5):829-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Cohorts of two to six patients received oral topotecan at 0.8, 1.1, 1.4, 1.8, and 2.3 mg/m(2)/d every 28 days for a maximum of six courses.
  • CONCLUSION: Oral topotecan (1.8 mg/m(2)/d) on a qd x 5 x 2 schedule is well tolerated and warrants additional testing in pediatric patients.
  • [MeSH-major] Maximum Tolerated Dose. Neoplasms / drug therapy. Salvage Therapy. Topotecan / administration & dosage. Topotecan / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Biological Availability. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Sampling Studies. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14990638.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA23099
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan
  •  go-up   go-down


76. Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Machowska L, Słuzewski W: Interleukin 6 and 12, alanine aminotransferase activity, and HCV viral load in children with chronic hepatitis C treated with interferon and ribavirin. Inflammation; 2004 Dec;28(6):319-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Alanine Transaminase / blood. Hepatitis C, Chronic / diagnosis. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Interleukin-12 / analysis. Interleukin-6 / analysis. Ribavirin / therapeutic use. Viral Load
  • [MeSH-minor] Antiviral Agents / therapeutic use. Child. Cohort Studies. Drug Therapy, Combination. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Humans. Male. Prognosis. RNA, Viral / blood. Recombinant Proteins. Time Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Viral Hepat. 1997;4 Suppl 2:83-6 [9429214.001]
  • [Cites] J Hepatol. 1996 Dec;25(6):827-32 [9007709.001]
  • [Cites] J Hepatol. 1998 Dec;29(6):1010-4 [9875652.001]
  • [Cites] Clin Liver Dis. 2001 Nov;5(4):931-53 [11685802.001]
  • [Cites] Hepatology. 1996 Apr;23 (4):669-75 [8666316.001]
  • [Cites] Int J Clin Pharmacol Ther. 1997 Sep;35(9):385-8 [9314092.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1847-55 [7908232.001]
  • [Cites] Clin Sci (Lond). 1997 Oct;93(4):381 [9404231.001]
  • [Cites] Hepatology. 1996 Oct;24(4):961-3 [8855206.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4008-27 [7994020.001]
  • [Cites] J Med Virol. 1998 Apr;54(4):265-70 [9580373.001]
  • [Cites] Immunopharmacol Immunotoxicol. 1995 May;17(2):347-64 [7650295.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):181-7 [9334839.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205 [8108387.001]
  • [Cites] J Immunol. 1986 Apr 1;136(7):2348-57 [2419430.001]
  • [Cites] Curr Opin Infect Dis. 1999 Jun;12(3):245-50 [17035787.001]
  • [Cites] J Gastroenterol. 1997 Apr;32(2):211-5 [9085170.001]
  • (PMID = 16245074.001).
  • [ISSN] 0360-3997
  • [Journal-full-title] Inflammation
  • [ISO-abbreviation] Inflammation
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Interleukin-6; 0 / RNA, Viral; 0 / Recombinant Proteins; 187348-17-0 / Interleukin-12; 43K1W2T1M6 / interferon alfa-2b; 49717AWG6K / Ribavirin; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


77. Sood A, Midha V, Sood N, Awasthi G: Chronic hepatitis C--treatment results in northern India. Trop Gastroenterol; 2002 Oct-Dec;23(4):172-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment had to be stopped in 3 patients due to major side effects like psychiatric disorders (2) and hypotension (1) and 3 patients were lost to follow up during the course of therapy.
  • Major side effects with the antiviral drugs necessitating drug withdrawal is infrequent.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Ribavirin / therapeutic use
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Drug Therapy, Combination. Female. Humans. India. Male. Middle Aged. Recombinant Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12833703.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 49717AWG6K / Ribavirin; 99210-65-8 / interferon alfa-2b; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


78. Hüser N, Doll D, Altomonte J, Werner M, Kriner M, Preissel A, Thorban S, Matevossian E: Graft preconditioning with low-dose tacrolimus (FK506) and nitric oxide inhibitor aminoguanidine (AGH) reduces ischemia/reperfusion injury after liver transplantation in the rat. Arch Pharm Res; 2009 Feb;32(2):215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fortyone DA-(RT1av1) rats served as donors and recipients for syngenic orthotopic arterialised LTx.
  • They were divided into 4 groups: controls without pre-/treatment (I), pre-/treatment with high-dose FK506 (II), pre-/treatment with AGH only (III), and pre-/treatment with low-dose FK506 in combination with AGH (IV).
  • The levels of transaminase (ALT) in groups I, II and III were significantly higher on day 3 after LTx compared to group IV (p = 0.001, p = 0.001, p = 0.000).
  • In group IV the I/R-associated liver necrosis rate was reduced significantly.
  • Our results demonstrated that a combined dual pharmacological pretreatment (group IV) reduced I/R injury of the graft after LTx in a rat model.
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Drug Therapy, Combination. Rats. Rats, Inbred Strains

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280151.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Guanidines; 31C4KY9ESH / Nitric Oxide; SCQ4EZQ113 / pimagedine; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


79. Conde Martel A, Gómez Arnáiz A, Aguiar Bautista JA, Santana Montesdeoca JM, Jorrín Moreno A, Suárez Ortega S: [Diagnostic usefulness of the questionnaire "Alcohol Use Disorders Identification Test" (AUDIT) to detect conditions associated with alcohol in hospitalized patients]. An Med Interna; 2000 Nov;17(11):576-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic usefulness of the questionnaire "Alcohol Use Disorders Identification Test" (AUDIT) to detect conditions associated with alcohol in hospitalized patients].
  • OBJECTIVE: To evaluate the diagnostic usefulness of AUDIT (Alcohol Use Disorders Identification Test) for detection of alcohol-related problems (ARP) among hospitalized patients, to assess the potential differences according to age or sex and to compare its diagnostic value with that of some other conventionally used measures (CAGE questionnaire and biological markers).
  • MATERIAL AND METHODS: This is a cross-sectional study for evaluation of diagnostic tests including 179 hospitalized patients in a Medicine Unit.
  • Among biological markers GGT and MCV should be highlighted with sensitivities of 83% and 74% and specificities of 53% and 74% respectively.
  • Its diagnostic usefulness being lower for females, similar for both age groups considered and clearly higher than that of other commonly used measures.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11322029.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


80. Govendir M, Canfield PJ, Emslie DR, Watson AD, Church DB: Evaluation of d,l-ethionine as a mechanism for pancreatic islet regeneration in dogs. Aust Vet J; 2002 Jan-Feb;80(1-2):75-82; discussion 82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: During ethionine administration all animals displayed vomiting, inappetence, diarrhoea (often with blood), weight loss and depression.
  • In most dogs, faecal examination demonstrated increased undigested starch and muscle, as well as increased digested and undigested fat, during ethionine administration or early during the recovery period, suggesting transient malassimilation.
  • [MeSH-major] Antimetabolites / adverse effects. Diabetes Mellitus, Type 1 / veterinary. Dog Diseases / drug therapy. Ethionine / adverse effects
  • [MeSH-minor] Alanine Transaminase / blood. Alkaline Phosphatase / blood. Amylases / blood. Animals. Bilirubin / blood. Blood Glucose. C-Peptide / blood. Creatinine / blood. Dogs. Female. Glucose Tolerance Test / veterinary. Injections, Intravenous / veterinary. Insulin / blood. Islets of Langerhans / drug effects. Jejunum / pathology. Kidney / pathology. Lipase / blood. Liver / pathology. Liver Function Tests / veterinary. Male. Pancreas / cytology. Pancreas / drug effects. Urea / blood

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • Hazardous Substances Data Bank. (L)-ETHIONINE .
  • Hazardous Substances Data Bank. UREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12180885.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Blood Glucose; 0 / C-Peptide; 0 / Insulin; 8W8T17847W / Urea; AYI8EX34EU / Creatinine; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.1.3 / Lipase; EC 3.1.3.1 / Alkaline Phosphatase; EC 3.2.1.- / Amylases; RFM9X3LJ49 / Bilirubin; WX1BN24WZT / Ethionine
  •  go-up   go-down


81. Xu C, Shu WQ, Qiu ZQ, Chen JA, Zhao Q, Cao J: Protective effects of green tea polyphenols against subacute hepatotoxicity induced by microcystin-LR in mice. Environ Toxicol Pharmacol; 2007 Sep;24(2):140-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mice in groups III, IV and V were daily pre-treated with GTP through intragastric administration at doses of 50, 100 and 200mg/kg/day from day 0 prior to MC-LR intoxication, consecutively 18 days.
  • GTP pre-treatment caused a significant elevation in serum antioxidant enzymes GSH and SOD activities as well as a decrease in hepatic lipid peroxidation MDA level and serum ALT, AST, ALP activities.
  • The results indicated that tea polyphenols have a potential to be developed as a preventive agent against MC-LR-induced toxicity and the mechanism involved in the protection could be due to their antioxidant activities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 Elsevier B.V. All rights reserved.
  • (PMID = 21783802.001).
  • [ISSN] 1382-6689
  • [Journal-full-title] Environmental toxicology and pharmacology
  • [ISO-abbreviation] Environ. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


82. Ray SD, Balasubramanian G, Bagchi D, Reddy CS: Ca(2+)-calmodulin antagonist chlorpromazine and poly(ADP-ribose) polymerase modulators 4-aminobenzamide and nicotinamide influence hepatic expression of BCL-XL and P53 and protect against acetaminophen-induced programmed and unprogrammed cell death in mice. Free Radic Biol Med; 2001 Aug 1;31(3):277-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study investigated the effect of AAP on the expression of these oncogenes and whether agents that modulate DNA fragmentation (chlorpromazine, CPZ) and DNA repair through poly(ADP-Ribose) polymerase (PARP) activity (4-AB: 4-aminobenzamide) can protect against AAP-induced hepatotoxicity by inhibiting oxidative stress, DNA fragmentation, and/or by altering the expression of bcl-XL and p53.
  • Male ICR mice (3 months old) were administered vehicle alone; nontoxic doses of 4-AB (400 mg/kg, ip), NICO (250 mg/kg, ip) or CPZ (25 mg/kg, ip), hepatotoxic dose of AAP alone (500 mg/kg, ip), or AAP plus one of the protective agents 1 h later.
  • All animals were sacrificed 24 h following AAP administration.
  • All of the three agents significantly prevented AAP-induced liver injury, lipid peroxidation, DNA damage, and associated apoptotic and necrotic cell deaths, 4-AB being the most effective and NICO the least.
  • The effect of AAP on bcl-XL was antagonized and that on p53 was synergized by the PARP-modulator 4-AB as well as NICO, whereas the endonuclease inhibitor CPZ was without effect on either bcl-XL or p53 expression.
  • [MeSH-major] 4-Aminobenzoic Acid / toxicity. Apoptosis / drug effects. Cell Death / drug effects. Chlorpromazine / toxicity. Lipid Peroxidation / drug effects. Liver / drug effects. Niacinamide / toxicity. Poly(ADP-ribose) Polymerase Inhibitors. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism. para-Aminobenzoates
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Benzamides. Biomarkers / blood. Blotting, Western. Calmodulin / antagonists & inhibitors. DNA Damage. DNA Fragmentation. Gene Expression Regulation / drug effects. Male. Mice. Mice, Inbred ICR. Oxidative Stress / drug effects. Radiation-Sensitizing Agents / pharmacology. bcl-X Protein

  • Hazardous Substances Data Bank. 4-AMINOBENZOIC ACID .
  • Hazardous Substances Data Bank. Chlorpromazine .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11461765.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bcl2l1 protein, mouse; 0 / Benzamides; 0 / Biomarkers; 0 / Calmodulin; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Radiation-Sensitizing Agents; 0 / Tumor Suppressor Protein p53; 0 / bcl-X Protein; 0 / para-Aminobenzoates; 25X51I8RD4 / Niacinamide; 2835-68-9 / 4-aminobenzamide; EC 2.6.1.2 / Alanine Transaminase; TL2TJE8QTX / 4-Aminobenzoic Acid; U42B7VYA4P / Chlorpromazine
  •  go-up   go-down


83. Yoshie H, Tai H, Kobayashi T, Oda-Gou E, Nomura Y, Numabe Y, Ito K, Kurihara H, Kamoi K: Salivary enzyme levels after scaling and interleukin-1 genotypes in Japanese patients with chronic periodontitis. J Periodontol; 2007 Mar;78(3):498-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Saliva has been used as a diagnostic fluid in medicine and dentistry.
  • A significant difference was set at P <0.05.
  • No difference was noted in the decrease in PD, CAL, and BOP after scaling between the carriers (N = 12) and non-carriers (N = 37) of IL-1A+4845 allele 2.
  • However, the IL-1A allele 2 non-carriers displayed a significant decrease in salivary AST and ALT levels (P <0.001), in contrast to the carriers who did not show any changes in the salivary levels of the enzymes after scaling.
  • CONCLUSIONS: These results documented that salivary AST, ALT, and LDH levels reflect inflammation and destruction of periodontal tissue, suggesting clinically useful markers following periodontal therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17335373.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interleukin-1; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


84. Yang Q, Gong ZJ, Hu DF: [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period]. Zhonghua Gan Zang Bing Za Zhi; 2007 Nov;15(11):821-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), Alb, TBil, HBeAg, HBV DNA, PCIII, IVC, LN, and HA, renal function, Child-Pugh scores and drug adverse reactions during the treatment of the two groups were checked, compared and analyzed.
  • No drug related renal function impairment was found during the treatment.
  • Two patients of each group had adverse drug reactions but all were mild.
  • [MeSH-major] Adenine / analogs & derivatives. Antiviral Agents / therapeutic use. Hepatitis, Chronic / drug therapy. Lamivudine / therapeutic use. Liver Cirrhosis / drug therapy. Organophosphonates / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Resistance, Viral. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18073064.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 2T8Q726O95 / Lamivudine; JAC85A2161 / Adenine; U6Q8Z01514 / adefovir dipivoxil
  •  go-up   go-down


86. Tasaki M, Umemura T, Inoue T, Okamura T, Kuroiwa Y, Ishii Y, Maeda M, Hirose M, Nishikawa A: Induction of characteristic hepatocyte proliferative lesion with dietary exposure of Wistar Hannover rats to tocotrienol for 1 year. Toxicology; 2008 Sep 4;250(2-3):143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since 6 animals in the 2% male group died of hemorrhage of several organs by week 50, the maximum dose level was changed to 1% in both sexes for the last 2 weeks.
  • At necropsy, multiple cyst-like nodules on the liver surface were macroscopically pronounced in both sexes receiving 2%.
  • On histopathological examination, hepatocellular nodules were evident with distortion of hepatic cords and compression of the surrounding tissue, almost all including areas of spongiosis hepatis.
  • [MeSH-major] Antioxidants / pharmacology. Cell Proliferation / drug effects. Diet. Hepatocytes / physiology. Tocotrienols / pharmacology
  • [MeSH-minor] Animals. Blood Cell Count. Blood Chemical Analysis. Body Weight / drug effects. Eating / drug effects. Female. Glutathione Transferase / metabolism. Immunohistochemistry. Liver Neoplasms, Experimental / chemically induced. Liver Neoplasms, Experimental / pathology. Male. Organ Size / drug effects. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675878.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Tocotrienols; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


87. Netopilová M, Drsata J, Beránek M, Palicka V: New potential nonsteroidal anti-inflammatory drugs with antileukotrienic effects: influence on model proteins with catalytic activity. Acta Medica (Hradec Kralove); 2002;45(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New potential nonsteroidal anti-inflammatory drugs with antileukotrienic effects: influence on model proteins with catalytic activity.
  • Unspecific and side effects caused by interaction with proteins belong to common problems of many structures synthesized as potential medicaments.
  • Possible in vitro interactions with proteins of a group of phenylsulfonyl benzoic acid derivatives (VUFB 19363, 19369, 19370, 19371, and 19760) as new potential anti-inflammatory compounds with anti-leukotrienic activities were studied in the present work.
  • Three purified enzymes were used as model proteins with catalytic activities: Pig heart aspartate aminotransferase (AST, EC 2.6.1.1), alanine aminotransferase (ALT, EC 2.6.1.2), and glutamate decarboxylase (GAD, EC 4.1.1.15) from E. coli.
  • Catalytic activities during incubation of individual compounds (6 x 10(-5) M solution to 5 x 10(-2) M suspension) at 37 degrees C with enzymes served as criteria of stability and function of the proteins.
  • The lack of an immediate effect of compounds and the stability of enzymes during incubation them are favorable and support the prospective of the compounds as potential drugs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12143113.001).
  • [ISSN] 1211-4286
  • [Journal-full-title] Acta medica (Hradec Kralove)
  • [ISO-abbreviation] Acta Medica (Hradec Kralove)
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Benzoates; 0 / Enzymes; 0 / Leukotriene Antagonists; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 4.1.1.15 / Glutamate Decarboxylase
  •  go-up   go-down


88. Susic D, Varagic J, Ahn J, Frohlich ED: Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats. Am J Hypertens; 2004 Apr;17(4):328-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats.
  • BACKGROUND: Increased formation of advanced glycosylation end-products on body proteins is a consequence of aging and leads to exaggerated collagen cross-linking eventually increasing cardiovascular stiffness.
  • This study reports our initial inquires into the cardiovascular and renal effects of a cross-link breaker (ALT-711) in aged spontaneously hypertensive rats (SHR).
  • [MeSH-major] Cardiovascular System / drug effects. Kidney / drug effects. Thiazoles / administration & dosage
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Cardiac Output / drug effects. Coronary Circulation / drug effects. Dose-Response Relationship, Drug. Heart Rate / drug effects. Heart Ventricles / drug effects. Heart Ventricles / metabolism. Hydroxyproline / drug effects. Hydroxyproline / metabolism. Liver / blood supply. Liver / drug effects. Male. Models, Animal. Models, Cardiovascular. Rats. Rats, Inbred SHR. Regional Blood Flow / drug effects. Vascular Resistance / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15062886.001).
  • [ISSN] 0895-7061
  • [Journal-full-title] American journal of hypertension
  • [ISO-abbreviation] Am. J. Hypertens.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiazoles; DGH49JXB1F / alagebrium; RMB44WO89X / Hydroxyproline
  •  go-up   go-down


89. Rahmioglu N, Andrew T, Cherkas L, Surdulescu G, Swaminathan R, Spector T, Ahmadi KR: Epidemiology and genetic epidemiology of the liver function test proteins. PLoS One; 2009;4(2):e4435
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and genetic epidemiology of the liver function test proteins.
  • BACKGROUND: The liver function test (LFT) is among the most commonly used clinical investigations to assess hepatic function, severity of liver diseases and the effect of therapies, as well as to detect drug-induced liver injury (DILI).
  • AIMS: To determine the relative contribution of genetic and environmental factors as well as test and quantify the effects of sex, age, BMI and alcohol consumption to variation in liver function test proteins--including alanine amino transaminase (ALT), Albumin, gamma glutamyl transpeptidase (GGT), total bilirubin, total protein, total globulin, aspartate transaminase (AST), and alkaline phosphotase (ALP)--using the classical twin model.
  • We measured the expression levels of major proteins associated with the LFT, calculated BMI from measured weight and height and questionnaires were completed for alcohol consumption by the twins.
  • The relative contribution of genetic and environmental factors to variation in the LFT proteins was assessed and quantified using a variance components model fitting approach.
  • CONCLUSIONS: Variation in the LFT proteins is under significant genetic and common environmental control although sex, alcohol use, age and BMI also contribute significantly to inter-individual variation in the LFT proteins.

  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2008 Mar 4;148(5):348-52 [18316753.001]
  • [Cites] Int J Eat Disord. 2007 Dec;40(8):746-50 [17610252.001]
  • [Cites] Twin Res. 2001 Dec;4(6):464-77 [11780939.001]
  • [Cites] Clin Chem. 2002 Sep;48(9):1426-31 [12194918.001]
  • [Cites] Alcohol Clin Exp Res. 2004 Jun;28(6):949-56 [15201638.001]
  • [Cites] N Engl J Med. 1972 Apr 6;286(14):748-57 [4554517.001]
  • [Cites] Clin Biochem. 1979 Dec;12(6):262-3 [43785.001]
  • [Cites] Clin Biochem. 1993 Aug;26(4):241-51 [8242887.001]
  • [Cites] Acta Genet Med Gemellol (Roma). 1992;41(4):261-73 [1342134.001]
  • [Cites] Alcohol Clin Exp Res. 1994 Jun;18(3):702-10 [7943679.001]
  • [Cites] Prim Care. 1996 Sep;23(3):551-60 [8888344.001]
  • [Cites] Int J Epidemiol. 1997 Feb;26(1):92-9 [9126508.001]
  • [Cites] Acta Gastroenterol Belg. 1999 Jan-Mar;62(1):16-20 [10333595.001]
  • [Cites] Ann Rheum Dis. 2005 Feb;64(2):309-10 [15231511.001]
  • [Cites] Wiad Lek. 2004;57(9-10):427-30 [15765756.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):753-6 [15966198.001]
  • [Cites] Scand J Gastroenterol. 2006 Apr;41(4):465-71 [16635916.001]
  • [Cites] J Bone Miner Res. 2006 Dec;21 Suppl 2:P22-7 [17229003.001]
  • [Cites] Twin Res Hum Genet. 2006 Dec;9(6):899-906 [17254428.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):889-94 [17352018.001]
  • [Cites] Twin Res Hum Genet. 2007 Oct;10(5):757-64 [17903117.001]
  • [Cites] Clin Chem. 2001 Jan;47(1):81-7 [11148181.001]
  • (PMID = 19209234.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / ; United Kingdom / Department of Health / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins
  • [Other-IDs] NLM/ PMC2636884
  •  go-up   go-down


90. Dang SS, Jia XL, Cheng YA, Chen YR, Liu EQ, Li ZF: Inhibitory effect of Huangqi Zhechong decoction on liver fibrosis in rat. World J Gastroenterol; 2004 Aug 1;10(15):2295-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Except for the normal control group, all the rats were subcutaneously injected with CCl(4) at a dosage of 3 mL/kg.
  • Enzyme-linked immunosorbent assay (ELISA) and biochemical examinations were used to determine the changes of alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronic acid (HA), laminin (LN), type-III-procollagen-N-peptide (PIIIP), and type IV collagen content in serum, and hydroxyproline (Hyp) content in liver after sacrificing the rats.
  • RESULTS: Compared with the model control group, serum ALT, AST, HA, LN, PIIIP and type IV collagen levels dropped markedly in Huangqi Zhechong decoction groups, especially in the medium-dose Huangqi Zhechong decoction group (1 954+/-576 U/L vs 759+/-380 U/L, 2 735+/-786 U/L vs 1 259+/-829 U/L, 42.74+/-7.04 ng/mL vs 20.68+/-5.85 ng/mL, 31.62+/-5.84 ng/mL vs 14.87+/-1.45 ng/mL, 3.26+/-0.69 ng/mL vs 1.47+/-0.46 ng/mL, 77.68+/-20.23 ng/mL vs 25.64+/-4.68 ng/mL, respectively) (P<0.05).
  • The Hyp content in liver tissue was also markedly decreased (26.47+/-11.24 mg/mgprot vs 9.89+/-3.74 mg/mgprot) (P<0.01).
  • It may be a safe and effective therapeutic drug for patients with fibrosis.
  • [MeSH-major] Drugs, Chinese Herbal / pharmacology. Liver Cirrhosis / blood. Liver Cirrhosis / pathology
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Liver / pathology. Male. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15259087.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC4724985
  •  go-up   go-down


91. Qiu J, Liu Z, Da L, Li Y, Xuan H, Lin Q, Li F, Wang Y, Li Z, Zhao M: Overexpression of the gene for transmembrane 4 superfamily member 4 accelerates liver damage in rats treated with CCl4. J Hepatol; 2007 Feb;46(2):266-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Drug-Induced Liver Injury / genetics. Drug-Induced Liver Injury / pathology. Liver / pathology. Membrane Glycoproteins / genetics. Transcriptional Activation
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Apoptosis / genetics. Aspartate Aminotransferases / blood. Blotting, Western. Carbon Tetrachloride / toxicity. DNA, Antisense / genetics. Gene Expression. Hepatocytes / pathology. Male. Necrosis. Proto-Oncogene Proteins c-met / genetics. Proto-Oncogene Proteins c-met / metabolism. Rats. Rats, Sprague-Dawley. Receptors, Tumor Necrosis Factor, Type I / genetics. Receptors, Tumor Necrosis Factor, Type I / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. CARBON TETRACHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069928.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Antisense; 0 / Membrane Glycoproteins; 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Tm4sf4 protein, rat; 0 / Tnfrsf1a protein, rat; 0 / Tumor Necrosis Factor-alpha; CL2T97X0V0 / Carbon Tetrachloride; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


92. Suda I, Ishikawa F, Hatakeyama M, Miyawaki M, Kudo T, Hirano K, Ito A, Yamakawa O, Horiuchi S: Intake of purple sweet potato beverage affects on serum hepatic biomarker levels of healthy adult men with borderline hepatitis. Eur J Clin Nutr; 2008 Jan;62(1):60-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the 8-week intervention, the subjects in the PSP group consumed two bottles of the PSP beverage with acylated anthocyanins (200.3 mg anthocyanins per 125 ml per bottle) per day, and the subjects in the placebo group, two bottles of a placebo beverage (1.7 mg anthocyanins per 125 ml per bottle).
  • [MeSH-major] Anthocyanins / therapeutic use. Ipomoea batatas / chemistry. Liver / drug effects. Liver / enzymology. Liver Function Tests
  • [MeSH-minor] Adult. Alanine Transaminase / metabolism. Aspartate Aminotransferases / metabolism. Beverages. Biomarkers / blood. Double-Blind Method. Hepatitis / blood. Hepatitis / drug therapy. Humans. Male. Middle Aged. gamma-Glutamyltransferase / metabolism

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17299464.001).
  • [ISSN] 0954-3007
  • [Journal-full-title] European journal of clinical nutrition
  • [ISO-abbreviation] Eur J Clin Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthocyanins; 0 / Biomarkers; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


93. Lin H, Zhu G, Xing J, Gao B, Qiu S: Polymer-mesoporous silica materials templated with an oppositely charged surfactant/polymer system for drug delivery. Langmuir; 2009 Sep 1;25(17):10159-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymer-mesoporous silica materials templated with an oppositely charged surfactant/polymer system for drug delivery.
  • Using the materials as the host and ibuprofen (IBU)/captopril (CapH(2)) as the model drugs, the system revealed well-sustained release profiles.
  • [MeSH-major] Drug Delivery Systems. Polymers / chemistry. Silicon Dioxide / chemistry. Surface-Active Agents / chemistry

  • Hazardous Substances Data Bank. IBUPROFEN .
  • Hazardous Substances Data Bank. CAPTOPRIL .
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19552374.001).
  • [ISSN] 0743-7463
  • [Journal-full-title] Langmuir : the ACS journal of surfaces and colloids
  • [ISO-abbreviation] Langmuir
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cations; 0 / Ions; 0 / Polymers; 0 / Surface-Active Agents; 7631-86-9 / Silicon Dioxide; 9G64RSX1XD / Captopril; N762921K75 / Nitrogen; WK2XYI10QM / Ibuprofen
  •  go-up   go-down


94. Li JX: [The effect of entecavir treatment on HBV-specific immunity in patient with chronic hepatitis B and its relationship to HBeAg sero-conversion]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr;22(2):122-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antiviral Agents / therapeutic use. Guanine / analogs & derivatives. Hepatitis B e Antigens / blood. Hepatitis B virus / drug effects. Hepatitis B, Chronic / drug therapy
  • [MeSH-minor] Adult. Cell Proliferation / drug effects. DNA, Viral / blood. DNA, Viral / genetics. Female. Humans. Interferon-alpha / blood. Male. T-Lymphocytes / cytology. T-Lymphocytes / drug effects. Time Factors. Transaminases / blood. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574534.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Hepatitis B e Antigens; 0 / Interferon-alpha; 5968Y6H45M / entecavir; 5Z93L87A1R / Guanine; EC 2.6.1.- / Transaminases
  •  go-up   go-down


95. Kim JC, Shin DH, Ahn TH, Kang SS, Song SW, Han J, Kim CY, Ha CS, Chung MK: 26-Week repeated oral dose toxicity study of the new quinolone antibacterial DW-116 in Sprague-Dawley rats. Food Chem Toxicol; 2003 May;41(5):637-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on these results, it was concluded that the 26-week repeated oral dose of DW-116 caused increases in the liver weight, WBC counts, total bilirubin and ALT values in males at a dose level of 125 mg/kg/day.
  • [MeSH-major] Anti-Infective Agents / toxicity. Fluoroquinolones. Liver / pathology. Piperazines / toxicity. Quinolones / toxicity
  • [MeSH-minor] Administration, Oral. Alanine Transaminase / analysis. Animals. Bilirubin / analysis. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Leukocyte Count. Male. No-Observed-Adverse-Effect Level. Rats. Rats, Sprague-Dawley. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12659716.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / DW-116; 0 / Fluoroquinolones; 0 / Piperazines; 0 / Quinolones; EC 2.6.1.2 / Alanine Transaminase; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


96. Pollak PT, Shafer SL: Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther; 2004 Apr;75(4):342-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Amiodarone causes hepatotoxicity in experimental models, but in humans, the relationships between drug administration, serum concentrations, markers of liver function, and how to monitor for hepatotoxicity have not been well characterized.
  • [MeSH-major] Amiodarone / adverse effects. Anti-Arrhythmia Agents / adverse effects. Drug-Induced Liver Injury. Liver Diseases / prevention & control. Mass Screening / methods. Nonlinear Dynamics. Transaminases / drug effects
  • [MeSH-minor] Aged. Arrhythmias, Cardiac / diagnosis. Arrhythmias, Cardiac / drug therapy. Biomarkers / analysis. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Liver / drug effects. Liver Function Tests. Male. Maximum Tolerated Dose. Middle Aged. Monitoring, Physiologic. Prospective Studies. Risk Assessment. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15060512.001).
  • [ISSN] 0009-9236
  • [Journal-full-title] Clinical pharmacology and therapeutics
  • [ISO-abbreviation] Clin. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Biomarkers; EC 2.6.1.- / Transaminases; N3RQ532IUT / Amiodarone
  •  go-up   go-down


97. Puoti C, Bellis L, Galossi A, Guarisco R, Nicodemo S, Spilabotti L, Unto OD: Antiviral treatment of HCV carriers with persistently normal ALT levels. Mini Rev Med Chem; 2008 Feb;8(2):150-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral treatment of HCV carriers with persistently normal ALT levels.
  • The prevalence of HCV carriers with normal liver seems to be very low (less than 15-20%).
  • Although the majority of data seem to show that HCV carriers with normal ALT have mild and stable disease, with a favourable prognosis, several studies reported a significant progression of fibrosis in approximately 20-30% of the patients with ALT normality, and the development of HCC in some cases has been described, despite persistent ALT normality.
  • [MeSH-major] Alanine Transaminase / metabolism. Antiviral Agents / therapeutic use. Carrier State / drug therapy. Carrier State / enzymology. Hepatitis C, Chronic / drug therapy. Hepatitis C, Chronic / enzymology
  • [MeSH-minor] Hepacivirus / drug effects. Hepacivirus / physiology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289098.001).
  • [ISSN] 1389-5575
  • [Journal-full-title] Mini reviews in medicinal chemistry
  • [ISO-abbreviation] Mini Rev Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.6.1.2 / Alanine Transaminase
  • [Number-of-references] 40
  •  go-up   go-down


98. Tremlett H, Oger J: Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol; 2004 Nov;251(11):1297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Males are more likely than females to develop elevated aminotransferases (> upper normal limit), although females appear at a greater risk of severe liver injury.
  • Whilst many other factors can affect liver test results, including obesity, alcohol, concomitant medications, co-morbidities and theoretically even MS itself, regular liver testing both prior and during IFNB therapy might help minimise Type A or dose/frequency dependent aminotransferase elevations.
  • However, testing will probably not prevent the Type B idiosyncratic reactions which can result in severe hepatic injury; hence patients need to be aware, and to report hepatic side effects promptly.
  • [MeSH-major] Chemical and Drug Induced Liver Injury. Interferon-beta / adverse effects. Multiple Sclerosis / drug therapy
  • [MeSH-minor] Aspartate Aminotransferases / metabolism. Drug Monitoring / methods. Humans. Liver Diseases / enzymology. Liver Function Tests / methods. Predictive Value of Tests. Product Surveillance, Postmarketing. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2002;37(8):617-25 [12203077.001]
  • [Cites] Am J Gastroenterol. 1996 Oct;91(10 ):2233-4 [8855756.001]
  • [Cites] Ann Neurol. 1996 Mar;39(3):285-94 [8602746.001]
  • [Cites] Semin Oncol. 1992 Oct;19(5):551-65 [1411653.001]
  • [Cites] J Clin Pharm Ther. 2001 Dec;26(6):437-44 [11722681.001]
  • [Cites] Arterioscler Thromb. 1992 Sep;12(9):1053-62 [1525120.001]
  • [Cites] Lancet. 1998 Nov 7;352(9139):1498-504 [9820297.001]
  • [Cites] Can J Gastroenterol. 1998 Sep;12(6):417-21 [9784897.001]
  • [Cites] Ann Intern Med. 2002 Jul 2;137(1):49-51 [12093245.001]
  • [Cites] Neurology. 2001 May 22;56(10):1416 [11376205.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):345 [11182855.001]
  • [Cites] Mil Med. 1978 Aug;143(8):548-51 [99696.001]
  • [Cites] J Neurol. 2002 Jan;249(1):50-6 [11954868.001]
  • [Cites] Atherosclerosis. 1987 Oct;67(2-3):261-7 [3079540.001]
  • [Cites] Arthritis Rheum. 2002 Jul;46(7):1851-6 [12124869.001]
  • [Cites] Am J Med. 1992 Apr;92(4):433-6 [1558090.001]
  • [Cites] Neurology. 1993 Apr;43(4):655-61 [8469318.001]
  • [Cites] N Engl J Med. 1989 Sep 14;321(11):762-3 [2770807.001]
  • [Cites] Brain. 2002 May;125(Pt 5):952-60 [11960885.001]
  • [Cites] Ann Ital Med Int. 2000 Jul-Sep;15(3):214-7 [11059062.001]
  • [Cites] Pharmacol Ther. 2001 Nov-Dec;92(2-3):147-63 [11916535.001]
  • [Cites] Am J Clin Oncol. 1993 Apr;16(2):159-63 [8452111.001]
  • [Cites] Can J Neurol Sci. 1987 Aug;14(3 Suppl):513-7 [3676923.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):77-88 [10728796.001]
  • [Cites] Drug Saf. 2003;26(11):815-27 [12908850.001]
  • [Cites] Acta Physiol Scand. 1999 Nov;167(3):259-65 [10606828.001]
  • [Cites] Regul Toxicol Pharmacol. 1998 Apr;27(2):119-30 [9671567.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1266-71 [10781624.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1954 Apr;71(4):405-24 [13147599.001]
  • [Cites] Br J Clin Pharmacol. 1988 Jul;26(1):1-5 [3203052.001]
  • [Cites] J Gastroenterol. 2002 Jan;37(1):40-6 [11824799.001]
  • [Cites] Neurology. 1990 Sep;40(9):1427-32 [2392230.001]
  • [Cites] Am J Med. 1999 Feb;106(2):267-8 [10230761.001]
  • [Cites] Lancet. 1989 May 20;1(8647):1143 [2566087.001]
  • [Cites] Neurology. 2001 Oct 23;57(8):1363-70 [11673572.001]
  • [Cites] Neurology. 1998 Feb;50(2):570-1 [9484407.001]
  • [Cites] Am J Med Sci. 1999 May;317(5):336-40 [10334121.001]
  • [Cites] Lancet. 1967 Apr 22;1(7495):896 [4164387.001]
  • [Cites] Autoimmunity. 2003 May;36(3):133-41 [12911279.001]
  • [Cites] J Hepatol. 1990 Sep;11(2):272-6 [2254635.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):474-85 [12890847.001]
  • [Cites] Gut. 1991 Jun;32(6):715-7 [2060883.001]
  • [Cites] Clin Chem Lab Med. 2000 Mar;38(3):209-13 [10905756.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):767-8 [11922585.001]
  • [Cites] Lancet. 2000 Feb 19;355(9204):591-2 [10696975.001]
  • [Cites] Arch Intern Med. 2002 Apr 8;162(7):811-5 [11926856.001]
  • [Cites] Neurology. 2002 Jan 22;58(2):169-78 [11805241.001]
  • [Cites] Neurology. 2004 Feb 24;62(4):628-31 [14981183.001]
  • (PMID = 15592724.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 77238-31-4 / Interferon-beta; EC 2.6.1.1 / Aspartate Aminotransferases
  • [Number-of-references] 59
  •  go-up   go-down


99. Liang J, Zhang XL, Yang GY, Pang YS, Yuan HF, Liang JS, Huang RB: [Observation of the promotion effect taurine on hepatic stellate cell's apoptosis in rat hepatic fibrosis model]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May;36(3):365-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum alanine aminotransferase (ALT), plasma protein, hyaluronic acid (HA), procollagen III (PC III), hepatic microsomal drug-metabolizing enzyme and anti-transforming growth factor beta1 (TGF-beta1) were determined.
  • In addition, hepatic stellate cell's apoptosis and the pathological changes of liver tissue were observed under light microscope.
  • [MeSH-major] Apoptosis / drug effects. Liver / pathology. Liver Cirrhosis / drug therapy. Taurine / pharmacology. Transforming Growth Factor beta / biosynthesis
  • [MeSH-minor] Animals. Carbon Tetrachloride Poisoning. Hepatocytes / drug effects. Male. Random Allocation. Rats. Rats, Wistar. Transforming Growth Factor beta1

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. Taurine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15931870.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tgfb1 protein, rat; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 1EQV5MLY3D / Taurine
  •  go-up   go-down


100. Kang KW, Choi SH, Ha JR, Kim CW, Kim SG: Inhibition of dimethylnitrosamine-induced liver fibrosis by [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) in rats: suppression of transforming growth factor-beta1 and tumor necrosis factor-alpha expression. Chem Biol Interact; 2002 Jan 22;139(1):61-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of dimethylnitrosamine-induced liver fibrosis by [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) in rats: suppression of transforming growth factor-beta1 and tumor necrosis factor-alpha expression.
  • Oltipraz is a cancer chemopreventive agent active against a wide variety of chemical carcinogens.
  • As part of mechanistic studies, the expression of transforming growth factor-beta1 (TGF-beta1) and tumor necrosis factor-alpha (TNF-alpha) was monitored.
  • [MeSH-major] Dimethylnitrosamine / toxicity. Liver Cirrhosis, Experimental / prevention & control. Pyrazines / therapeutic use. Transforming Growth Factor beta / antagonists & inhibitors. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Animals. Base Sequence. DNA Primers. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. RNA, Messenger / biosynthesis. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. N-NITROSODIMETHYLAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11803029.001).
  • [ISSN] 0009-2797
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Pyrazines; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; 6N510JUL1Y / oltipraz; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; M43H21IO8R / Dimethylnitrosamine
  •  go-up   go-down






Advertisement